false12-312021FY0000844856NONEP24MP24M0.05P24MP24MP2Y68800008448562021-01-012021-12-3100008448562021-06-3000008448562022-03-1800008448562021-12-3100008448562020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMember2021-12-310000844856hcmc:SeriesDConvertiblePreferredStockMember2020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMember2020-12-310000844856hcmc:SeriesDConvertiblePreferredStockMember2021-12-310000844856hcmc:VaporMember2020-01-012020-12-310000844856hcmc:GroceryMember2020-01-012020-12-310000844856hcmc:VaporMember2021-01-012021-12-310000844856hcmc:GroceryMember2021-01-012021-12-3100008448562020-01-012020-12-310000844856us-gaap:AdditionalPaidInCapitalMember2019-12-3100008448562019-12-310000844856us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2019-12-310000844856us-gaap:CommonStockMember2019-12-310000844856us-gaap:RetainedEarningsMember2019-12-310000844856us-gaap:CommonStockMember2020-01-012020-12-310000844856us-gaap:PreferredStockMember2020-01-012020-12-310000844856us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000844856us-gaap:RetainedEarningsMember2020-01-012020-12-310000844856us-gaap:PreferredStockMember2021-01-012021-12-310000844856us-gaap:CommonStockMember2021-01-012021-12-310000844856us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000844856us-gaap:RetainedEarningsMember2021-01-012021-12-310000844856hcmc:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310000844856us-gaap:AdditionalPaidInCapitalMemberhcmc:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310000844856us-gaap:CommonStockMemberhcmc:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310000844856hcmc:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310000844856us-gaap:RetainedEarningsMemberhcmc:SeriesBConvertiblePreferredStockMember2020-01-012020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMember2020-01-012020-12-310000844856us-gaap:AdditionalPaidInCapitalMemberhcmc:SeriesCConvertiblePreferredStockMember2020-01-012020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMemberus-gaap:RetainedEarningsMember2020-01-012020-12-310000844856hcmc:SeriesCConvertiblePreferredStockMemberus-gaap:CommonStockMember2020-01-012020-12-310000844856hcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-12-310000844856us-gaap:PreferredStockMemberhcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-12-310000844856us-gaap:CommonStockMemberhcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-12-310000844856us-gaap:AdditionalPaidInCapitalMemberhcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-12-310000844856us-gaap:RetainedEarningsMemberhcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-12-310000844856hcmc:SeriesCConvertiblePreferredStockMemberus-gaap:CommonStockMember2021-01-012021-12-310000844856us-gaap:PreferredStockMemberhcmc:SeriesCConvertiblePreferredStockMember2021-01-012021-12-310000844856hcmc:SeriesCConvertiblePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000844856hcmc:SeriesCConvertiblePreferredStockMember2021-01-012021-12-310000844856us-gaap:RetainedEarningsMemberhcmc:SeriesCConvertiblePreferredStockMember2021-01-012021-12-310000844856srt:BoardOfDirectorsChairmanMember2021-01-012021-12-310000844856us-gaap:PreferredStockMembersrt:BoardOfDirectorsChairmanMember2021-01-012021-12-310000844856us-gaap:CommonStockMembersrt:BoardOfDirectorsChairmanMember2021-01-012021-12-310000844856us-gaap:AdditionalPaidInCapitalMembersrt:BoardOfDirectorsChairmanMember2021-01-012021-12-310000844856srt:OfficerMemberus-gaap:PreferredStockMember2021-01-012021-12-310000844856us-gaap:RetainedEarningsMembersrt:BoardOfDirectorsChairmanMember2021-01-012021-12-310000844856srt:OfficerMember2021-01-012021-12-310000844856srt:OfficerMemberus-gaap:RetainedEarningsMember2021-01-012021-12-310000844856srt:OfficerMemberus-gaap:CommonStockMember2021-01-012021-12-310000844856us-gaap:AdditionalPaidInCapitalMembersrt:OfficerMember2021-01-012021-12-310000844856us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2021-12-310000844856us-gaap:CommonStockMember2021-12-310000844856us-gaap:RetainedEarningsMember2020-12-310000844856us-gaap:AdditionalPaidInCapitalMember2020-12-310000844856us-gaap:CommonStockMember2020-12-310000844856us-gaap:RetainedEarningsMember2021-12-310000844856us-gaap:AdditionalPaidInCapitalMember2021-12-310000844856us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2020-12-310000844856hcmc:MotherEarthSStorehouseMemberus-gaap:SubsequentEventMember2022-02-280000844856hcmc:MotherEarthSStorehouseMember2021-01-012021-12-310000844856us-gaap:SalesRevenueNetMemberhcmc:VendorMemberus-gaap:SupplierConcentrationRiskMember2021-01-012021-12-310000844856us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberhcmc:VendorMember2020-01-012020-12-310000844856hcmc:VaporLoyaltyRewardsMember2021-01-012021-12-310000844856hcmc:GiftCardsMember2021-01-012021-12-310000844856hcmc:GroceryLoyaltyRewardsMember2021-01-012021-12-310000844856hcmc:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000844856us-gaap:AccountsReceivableMemberhcmc:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310000844856us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberhcmc:CustomerThreeMember2021-01-012021-12-310000844856hcmc:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000844856us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberhcmc:CustomerOneMember2021-01-012021-12-310000844856us-gaap:CustomerConcentrationRiskMemberhcmc:CustomerThreeMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310000844856srt:MaximumMember2021-01-012021-12-310000844856srt:MinimumMember2021-01-012021-12-310000844856hcmc:RetailVaporMember2021-01-012021-12-310000844856hcmc:RetailGroceryMember2020-01-012020-12-310000844856hcmc:OnlineAndECommerceMember2020-01-012020-12-310000844856hcmc:RetailGroceryMember2021-01-012021-12-310000844856hcmc:WholesaleVaporMember2021-01-012021-12-310000844856hcmc:FoodServiceAndRestaurantMember2021-01-012021-12-310000844856hcmc:WholesaleGroceryMember2021-01-012021-12-310000844856hcmc:RetailVaporMember2020-01-012020-12-310000844856hcmc:OnlineAndECommerceMember2021-01-012021-12-310000844856hcmc:WholesaleGroceryMember2020-01-012020-12-310000844856hcmc:FoodServiceAndRestaurantMember2020-01-012020-12-310000844856hcmc:WholesaleVaporMember2020-01-012020-12-3100008448562018-12-3100008448562018-01-012018-12-310000844856us-gaap:MeasurementInputQuotedPriceMember2021-12-310000844856us-gaap:FairValueInputsLevel1Member2021-12-310000844856us-gaap:FairValueInputsLevel1Member2020-12-310000844856us-gaap:MeasurementInputQuotedPriceMember2020-12-310000844856hcmc:ThirdPartyMember2020-01-012020-12-310000844856hcmc:ThirdPartyMember2021-01-012021-12-310000844856hcmc:GroceryMember2020-12-310000844856hcmc:VaporMember2020-12-310000844856hcmc:GroceryMember2021-12-310000844856hcmc:VaporMember2021-12-310000844856hcmc:PromissoryNotesMember2021-01-012021-12-310000844856hcmc:PromissoryNotesMember2018-09-062018-09-060000844856hcmc:PromissoryNotesMember2021-08-312021-08-310000844856hcmc:PromissoryNotesMember2021-08-310000844856hcmc:PromissoryNotesMember2018-09-060000844856hcmc:PromissoryNotesMember2020-12-310000844856hcmc:PromissoryNotesMember2021-12-310000844856us-gaap:FurnitureAndFixturesMember2021-12-310000844856us-gaap:OtherMachineryAndEquipmentMember2020-12-310000844856us-gaap:LeaseholdImprovementsMember2020-12-310000844856hcmc:DisplaysMember2020-12-310000844856us-gaap:OtherMachineryAndEquipmentMember2021-12-310000844856hcmc:DisplaysMember2021-12-310000844856us-gaap:FurnitureAndFixturesMember2020-12-310000844856us-gaap:ComputerEquipmentMember2021-12-310000844856us-gaap:LeaseholdImprovementsMember2021-12-310000844856us-gaap:ComputerEquipmentMember2020-12-310000844856us-gaap:CustomerRelationshipsMembersrt:MaximumMember2020-01-012020-12-310000844856us-gaap:NoncompeteAgreementsMember2020-01-012020-12-310000844856us-gaap:PatentsMember2021-01-012021-12-310000844856us-gaap:TradeNamesMembersrt:MaximumMember2020-01-012020-12-310000844856srt:MinimumMemberus-gaap:TradeNamesMember2021-01-012021-12-310000844856us-gaap:CustomerRelationshipsMembersrt:MaximumMember2021-01-012021-12-310000844856us-gaap:NoncompeteAgreementsMember2021-01-012021-12-310000844856us-gaap:CustomerRelationshipsMembersrt:MinimumMember2021-01-012021-12-310000844856us-gaap:PatentsMember2020-01-012020-12-310000844856srt:MinimumMemberus-gaap:TradeNamesMember2020-01-012020-12-310000844856us-gaap:InternetDomainNamesMember2021-01-012021-12-310000844856srt:MaximumMemberus-gaap:TradeNamesMember2021-01-012021-12-310000844856srt:MinimumMemberus-gaap:CustomerRelationshipsMember2020-01-012020-12-310000844856us-gaap:TradeNamesMember2021-12-310000844856us-gaap:TradeNamesMember2020-12-310000844856us-gaap:InternetDomainNamesMember2021-12-310000844856us-gaap:CustomerRelationshipsMember2020-12-310000844856us-gaap:PatentsMember2020-12-310000844856us-gaap:NoncompeteAgreementsMember2021-12-310000844856us-gaap:CustomerRelationshipsMember2021-12-310000844856us-gaap:PatentsMember2021-12-310000844856us-gaap:NoncompeteAgreementsMember2020-12-310000844856hcmc:EIRHydrationMember2021-11-302021-11-300000844856hcmc:TermLoanCreditAgreementMember2021-12-310000844856hcmc:TermLoanCreditAgreementMember2020-12-310000844856us-gaap:LineOfCreditMember2020-12-310000844856hcmc:OtherDebtMember2020-12-310000844856hcmc:PaycheckProtectionProgramMember2020-12-310000844856hcmc:TermLoanAndSecurityAgreementMember2021-12-310000844856hcmc:OtherDebtMember2021-12-310000844856us-gaap:LineOfCreditMember2021-12-310000844856hcmc:TermLoanAndSecurityAgreementMember2020-12-310000844856hcmc:PaycheckProtectionProgramMember2021-12-310000844856us-gaap:LineOfCreditMember2021-11-030000844856us-gaap:LineOfCreditMember2021-11-032021-11-030000844856us-gaap:PrimeRateMemberhcmc:TermLoanCreditAgreementMember2018-01-012018-12-310000844856hcmc:TermLoanCreditAgreementMember2018-12-310000844856hcmc:PaycheckProtectionProgramMember2020-05-150000844856hcmc:TermLoanCreditAgreementMember2021-12-212021-12-210000844856hcmc:PaycheckProtectionProgramMember2021-01-012021-12-310000844856hcmc:PaycheckProtectionProgramMember2021-03-052021-03-050000844856hcmc:FontemVenturesBVMemberhcmc:FontemLicenseAgreementMember2021-01-012021-12-310000844856hcmc:FontemLicenseAgreementMemberhcmc:FontemVenturesBVMember2020-01-012020-12-310000844856hcmc:PhilipMorrisMember2020-11-300000844856srt:ChiefExecutiveOfficerMember2018-08-132018-08-130000844856hcmc:PresidentAndChiefOperatingOfficerMember2021-02-262021-02-260000844856srt:ChiefExecutiveOfficerMembersrt:MaximumMember2018-08-132018-08-130000844856srt:ChiefExecutiveOfficerMembersrt:MinimumMember2018-08-132018-08-130000844856srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2018-08-132018-08-130000844856srt:ChiefExecutiveOfficerMember2019-08-122019-08-120000844856srt:ChiefExecutiveOfficerMember2020-08-122020-08-120000844856hcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember2021-01-012021-12-310000844856hcmc:MedicalCostsMemberhcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember2021-01-012021-12-310000844856hcmc:TwoThousandAndNineEquityIncentivePlanMember2021-12-310000844856srt:MaximumMemberhcmc:TwoThousandAndFifteenEquityIncentivePlanMember2015-07-070000844856hcmc:TwoThousandAndFifteenEquityIncentivePlanMember2021-12-3100008448562021-06-182021-06-1800008448562021-06-180000844856hcmc:TermLoanAndSecurityAgreementMember2021-03-2900008448562021-03-292021-03-2900008448562021-03-290000844856hcmc:TermLoanAndSecurityAgreementMember2021-01-012021-12-310000844856srt:BoardOfDirectorsChairmanMembersrt:MaximumMember2021-12-310000844856hcmc:SeriesCConvertiblePreferredStockMember2020-11-170000844856srt:BoardOfDirectorsChairmanMember2021-12-310000844856hcmc:SecuritiesPurchaseAgreementMemberhcmc:SeriesDConvertiblePreferredStockMember2021-02-070000844856hcmc:SeriesCConvertiblePreferredStockMember2020-11-172020-11-170000844856hcmc:SeriesDConvertiblePreferredStockMember2021-09-300000844856us-gaap:CommonStockMember2021-01-012021-09-300000844856hcmc:SeriesDConvertiblePreferredStockMember2021-01-012021-09-300000844856us-gaap:WarrantMember2016-10-050000844856us-gaap:WarrantMember2020-07-270000844856us-gaap:CommonStockMemberus-gaap:WarrantMember2020-01-012020-12-310000844856us-gaap:RestrictedStockMembersrt:ChiefFinancialOfficerMember2018-08-132018-08-130000844856srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2018-08-132018-08-130000844856hcmc:OfficersAndADirectorMemberus-gaap:RestrictedStockMember2021-01-142021-01-140000844856us-gaap:RestrictedStockMembersrt:ChiefOperatingOfficerMember2018-08-132018-08-130000844856srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000844856srt:ChiefOperatingOfficerMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000844856us-gaap:RestrictedStockMembersrt:ChiefFinancialOfficerMember2021-01-012021-12-310000844856hcmc:OfficersAndADirectorMemberus-gaap:RestrictedStockMember2021-03-302021-03-300000844856us-gaap:RestrictedStockMemberhcmc:OfficersAndADirectorMember2021-06-292021-06-290000844856us-gaap:StockOptionMember2019-12-310000844856us-gaap:StockOptionMember2020-01-012020-12-310000844856us-gaap:StockOptionMember2021-01-012021-12-310000844856us-gaap:StockOptionMember2021-12-310000844856us-gaap:StockOptionMember2020-12-310000844856us-gaap:StockOptionMember2019-01-012019-12-310000844856us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000844856us-gaap:PreferredStockMember2020-01-012020-12-310000844856us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000844856us-gaap:PreferredStockMember2021-01-012021-12-310000844856srt:MaximumMember2021-12-310000844856us-gaap:DomesticCountryMember2021-12-310000844856us-gaap:StateAndLocalJurisdictionMemberhcmc:TaxYearNoExpirationDateMember2021-12-310000844856us-gaap:StateAndLocalJurisdictionMember2021-12-310000844856hcmc:TaxYearNoExpirationDateMemberus-gaap:DomesticCountryMember2021-12-310000844856hcmc:TaxYear2032Through2037Memberus-gaap:StateAndLocalJurisdictionMember2021-12-310000844856hcmc:TaxYear2032Through2037Memberus-gaap:DomesticCountryMember2021-12-3100008448562021-05-012021-05-310000844856us-gaap:OperatingSegmentsMemberhcmc:GroceryMember2020-01-012020-12-310000844856hcmc:VaporMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310000844856hcmc:VaporMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310000844856us-gaap:OperatingSegmentsMemberhcmc:GroceryMember2021-01-012021-12-310000844856hcmc:AssetPurchaseAgreementMemberus-gaap:SubsequentEventMemberhcmc:MotherEarthSStorehouseMember2022-02-082022-02-080000844856hcmc:AssetPurchaseAgreementMemberhcmc:MotherEarthSStorehouseMember2022-02-082022-02-080000844856srt:ChiefFinancialOfficerMemberus-gaap:SubsequentEventMember2022-02-022022-02-020000844856hcmc:PhilipMorrisMemberhcmc:PatentInfringementLitigationMemberus-gaap:SubsequentEventMember2022-02-222022-02-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shareshcmc:Storexbrli:purehcmc:Vendorhcmc:Segmenthcmc:Userhcmc:Lawsuit
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the fiscal year ended: December 31, 2021
or
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the transition period from: _____________ to
_____________
HEALTHIER CHOICES MANAGEMENT CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-36469
|
|
84-1070932
|
(State or Other Jurisdiction of Incorporation or
Organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
Address of Principal Executive Office: 3800 North 28th
Way Hollywood,
FL 33020
Registrant’s telephone number, including area code:
(305) 600-5004
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
HCMC
|
|
OTC Pink
Marketplace
|
Securities registered pursuant to Section 12(g) of the
Act:
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. ☐
Yes No ☒
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act.
☐
Yes No ☒
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. ☒ Yes ☐
No
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). ☒ Yes ☐
No
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant has filed a report on
and attestation to its management assessment of the effectiveness
of its internal controls over financial reporting under Section
4049b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit
report ☒
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). ☐ Yes
No☒
The aggregate market value of the voting and non-voting common
equity held by non-affiliates computed by reference to the price at
which the common equity was last sold as of the last business day
of the registrant’s most recently completed second fiscal quarter
was approximately $366.5 million based on the June 30, 2021 closing
price of $0.0011 per share.
Indicate the number of shares outstanding of each of the
registrant’s classes of common stock, as of the latest practicable
date: 339,741,632,384 shares outstanding as of March 31,
2022.
INDEX
|
Page
|
|
|
PART I
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART II
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART III
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART IV
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART I
Healthier Choices Management Corp. (the “Company”) is a holding
company focused on providing consumers with healthier daily choices
with respect to nutrition and other lifestyle
alternatives.
Through its wholly owned subsidiary HCMC Intellectual Property
Holdings, LLC, the Company manages and intends to expand on its
intellectual property portfolio.
Through its wholly owned subsidiaries, Healthy Choice Markets,
Inc., Healthy Choice Markets 2, LLC, and Healthy Choice Markets 3,
LLC, respectively, the Company operates:
•
|
Ada’s Natural Market, a natural and organic grocery store offering
fresh produce, bulk foods, vitamins and supplements, packaged
groceries, meat and seafood, deli, baked goods, dairy products,
frozen foods, health & beauty products and natural household
items (www.Adasmarket.com)
|
•
|
Paradise Health & Nutrition’s three stores that likewise offer
fresh produce, bulk foods, vitamins and supplements, packaged
groceries, meat and seafood, deli, baked goods, dairy products,
frozen foods, health & beauty products and natural household
items, (www.ParadiseHealthDirect.com)
|
•
|
The Company acquired Mother Earth’s
Storehouse on February 2022, which operates a two store organic and
health food and vitamin chain in New York’s Hudson Valley, which
has been in existence for over 40 years. (www.MotherEarthStorehouse.com)
|
Through its wholly owned subsidiary, Healthy Choice Wellness, LLC,
the Company operates:
•
|
Healthy Choice Wellness Center (Roslyn Heights, NY) a Company owned
IV therapy center offering multiple IV drip “cocktails” for clients
to choose from. These cocktails are designed to help boost
immunity, fight fatigue and stress, reduce inflammation, enhance
weight loss, and efficiently deliver anti-oxidants and anti-aging
mixes. Additionally, there are cocktails for health, beauty and
re-hydration. (www.Eirhydration.com,
though rebranded website coming soon)
|
•
|
The Company entered into a licensing agreement in February 2022
for
a Healthy Choice Wellness Center at the Casbah Spa & Salon in
Fort Lauderdale, FL, offering essentially the same services as the
Roslyn Heights, NY location. This center will be opening in the
second quarter of 2022.
|
Through its wholly owned subsidiary, Healthy U Wholesale, the
Company sells vitamins and supplements, as well as health,
beauty and personal care products on its website www.TheVitaminStore.com.
Additionally, the Company markets its patented Q-Unit™ and
Q-Cup® technology. Information on these products and the
technology is available on the Company’s website
at www.theQcup.com.
NATURAL AND ORGANIC GROCERIES AND DIETARY SUPPLEMENTS
BUSINESS
Local. Organic. Fresh. Three words that define Healthy Choice
Markets! With Ada's Natural Market, a full-service grocery
store and Greenleaf Grill, Ada’s flagship fast casual in-store
restaurant, serving Fort Myers, FL, along with three (3) Paradise
Health & Nutrition locations in the greater Melbourne, FL area,
and our two (2) newly acquired as of February 2022, Mother Earth’s
Storehouse locations in Hudson Valley, NY, all serving their
respective local communities. Our stores provide all-natural and
organic products in a friendly and helpful atmosphere, with aisles
of traditional grocery complete with frozen, healthy home, vitamins
& supplements, health & beauty, fresh produce, hormone and
antibiotic free meats and bulk foods. Ada's Natural Market and
Mother Earth’s Storehouse also offer chef-prepared ready-to-go
foods, a 100% organic juice & smoothie bar (available also at
two of our Paradise locations), and a free-trade coffee bar with
fresh-baked-daily baked goods.
Collectively, we focus on providing high-quality products at
affordable prices, exceptional customer service, nutrition
education and community outreach. We strive to generate long-term
relationships with our customers based on quality and service
by:
|
● |
selling only all-natural and organic groceries;
|
|
● |
offering affordable prices and a shopper-friendly retail
environment; and
|
|
● |
providing dine-in options at our Greenleaf Grill, Organic Juice
Bar, and our free-trade coffee bar.
|
Our History and Founding Principles
We are committed to maintaining the following founding principles,
which have helped foster our growth:
|
● |
Quality. Every product on our shelves must go through a rigorous
screening and approval process. Our mission includes providing the
highest quality groceries and supplements, Natural Grocers branded
products, European and United States Department of Agriculture
(USDA) certified organic and fresh produce at the best prices in
the industry.
|
|
● |
Community. The Ada’s, Paradise, and now Mother Earth’s Storehouse
brands have each been serving their respective communities for 40+
years.
|
|
● |
Employees. Our employees make our companies great. We work hard to
ensure that our employees are able to live a healthy, balanced
lifestyle. We support them with free nutrition education programs,
competitive pay and excellent benefits.
|
Our Market
We operate within the natural products retail industry, which is a
subset of the United States grocery industry and the dietary
supplement business. This industry includes conventional
supermarkets, natural, gourmet and specialty food markets, mass and
discount retailers, warehouse clubs, independent health food
stores, dietary supplement retailers, drug stores, farmers’
markets, food co-ops, mail order and online retailers and
multi-level marketers. Industry-wide sales of natural and organic
foods and dietary supplements have experienced meaningful growth
over the past several years, and we believe that growth will
continue for the foreseeable future.
We believe the growth in sales of natural and organic foods and
dietary supplements continues to be driven by numerous factors,
including:
|
● |
greater consumer focus on high-quality nutritional products;
|
|
● |
an
increased awareness of the importance of good nutrition to
long-term wellness;
|
|
● |
aging communities that are seeking healthy lifestyle
alternatives;
|
|
● |
heightened consumer awareness about the importance of food quality
and a desire to avoid pesticide residues, growth hormones,
artificial ingredients and genetically engineered ingredients in
foods;
|
|
● |
growing consumer concerns over the use of harmful chemical
additives in body care and household cleaning supplies;
|
|
● |
well-established natural and organic brands, which generate
additional industry awareness and credibility with consumers;
and
|
|
● |
the growth in the number of consumers with special dietary
requirements as a result of allergies, chemical sensitivities,
auto-immune disorders and other conditions.
|
Our Competitive Strengths
We are well-positioned to capitalize on favorable natural and
organic grocery and dietary supplement industry dynamics as a
result of the following competitive strengths:
Strict focus on high-quality natural and organic grocery
products. We offer high-quality products and brands,
including an extensive selection of widely-recognized natural and
organic food, dietary supplements, body care products, pet care
products and books. We offer our customers approximately 10,000
Stock Keeping Units (SKUs) of natural and organic products. We
believe our broad product offering enables our customers to shop
our stores for substantially all of their grocery and dietary
supplement purchases. In our grocery departments, we primarily sell
USDA certified organic produce and do not approve for sale grocery
products that are known to contain artificial colors, flavors,
preservatives or sweeteners or partially hydrogenated or
hydrogenated oils. In addition, we only sell pasture-raised,
humanely-raised dairy products. Consistent with this strategy, our
product selection does not include items that do not meet our
strict quality guidelines. Our store managers enhance our robust
product offering by customizing their stores’ selections to address
the preferences of local customers.
Engaging customer service experience based on education and
empowerment. We strive to offer consistently exceptional
customer service in a shopper-friendly environment, which we
believe creates a differentiated shopping experience, enhances
customer loyalty and generates repeat visits from our clientele. A
key aspect of our customer service model is to provide free
nutrition education to our customers. We believe this focus
provides an engaging retail experience while also empowering our
customers to make informed decisions about their health. We offer
our science-based nutrition education through our trained
employees, our newsletter and sales flyer, community out-reach
programs, one-on-one nutrition health coaching, nutrition classes
and cooking demonstrations.
Our Growth Strategies
We expect to pursue several strategies to continue our profitable
growth, including:
Expand our store base. We intend to expand our store base
through the acquisition of new stores.
Increase sales from existing customers. In order to increase
our average ticket and the number of customer transactions, we plan
to continue offering an engaging customer experience by providing
science-based nutrition education and a differentiated
merchandising strategy that delivers affordable, high-quality
natural and organic grocery products and dietary supplements. We
also plan to continue to utilize targeted marketing efforts to
reach our existing customers, which we anticipate will drive
customer transactions and convert occasional, single-category
customers into core, multi-category customers.
Grow our customer base. We plan to implement several
measures aimed at building our brand awareness and growing our
customer base, including: (i) redesigning our website (www.adasmarket.com)
to enhance functionality, create a more engaging user experience
and increase its reach and effectiveness; (ii) introducing customer
appreciation programs at all our stores; and (iii) developing new
collateral marketing materials. We believe offering nutrition
education has historically been one of our most effective marketing
strategies for reaching new customers and increasing the demand for
natural and organic groceries and dietary supplements in our
markets.
Improve operating margins. We expect to continue to improve
our operating margins as we benefit from investments we have made
or are making in fixed overhead and information technology. As we
add additional stores, we expect to achieve greater economies of
scale through sourcing and distribution. To achieve additional
operating margin expansion, we intend to further optimize
performance, maintain appropriate store labor levels and
effectively manage product selection and pricing.
Our Products
Product Selection Guidelines. We have a set of strict
quality guidelines covering all products we sell. For
example:
|
● |
we
do not approve for sale food known to contain artificial colors,
flavors, preservatives or sweeteners or partially hydrogenated or
hydrogenated oils or phthalates or parabens, regardless of the
proportion of its natural or organic ingredients;
|
● we
sell USDA certified organic produce; and
|
● |
we
sell meats naturally raised without hormones, antibiotics or
treatments and that were not fed animal by-products.
|
Our product review team analyzes all new products and approves them
for sale based on ingredients, price and uniqueness within the
current product set. We actively research new products in the
marketplace through our product vendors, private label
manufacturers, scientific findings, customer requests and general
trends in popular media. Our stores are able to fully merchandise
all departments by providing an extensive assortment of natural and
organic products. We do not believe we need to sell conventional
products to fill our selection, increase our margins or attract
more customers.
What We Sell. We operate both a full-service natural and
organic grocery stores and dietary supplement stores within our
retail locations. The following is a breakdown of our product
mix:
|
● |
Grocery. We offer a broad selection of natural and organic
grocery products with an emphasis on minimally processed and single
ingredient products that are not known to contain artificial
colors, flavors, preservatives or sweeteners or partially
hydrogenated or hydrogenated oils. Additionally, we carry a wide
variety of products associated with special diets such as gluten
free, vegetarian and non-dairy.
|
|
● |
Produce. We sell USDA-certified organic produce and source
from local, organic producers whenever feasible. Our selection
varies based on seasonal availability, and we offer a variety of
organic produce offerings that are not typically found at
conventional food retailers.
|
|
● |
Bulk Food and Private Label Products. We sell a wide
selection of private label repackaged bulk and other products,
including nuts, water, pasta, canned seafood, dried fruits, grains,
granolas, honey, eggs, herbs, spices and teas.
|
|
● |
Dry, Frozen and Canned Groceries. We offer a wide variety of
natural and organic dry, frozen and canned groceries, including
cereals, soups, baby foods, frozen entrees and snack items. We
offer a broad selection of natural chocolate bars, and energy,
protein and food bars.
|
|
● |
Meats and Seafood. We offer naturally-raised or organic meat
products. The meat products we offer come from animals that have
never been treated with antibiotics or hormones or fed animal
by-products. Additionally, we only buy from companies we believe
employ humane animal-raising practices. Our seafood items are
generally frozen at the time of processing and sold from our
freezer section, thereby ensuring freshness and reducing food
spoilage and safety issues.
|
|
● |
Dairy Products and Dairy Substitutes. We offer a broad
selection of natural and organic dairy products such as milk, eggs,
cheeses, yogurts and beverages, as well as non-dairy substitutes
made from almonds, coconuts, rice and soy.
|
|
● |
Prepared Foods. Our stores have a convenient selection of
refrigerated prepared fresh food items, including salads,
sandwiches, salsa, humus and wraps. The size of this offering
varies by location.
|
|
● |
Bread and Baked Goods. We receive regular deliveries of a
wide selection of bakery products for our bakery section, which
includes an extensive selection of gluten-free items.
|
|
● |
Beverages. We offer a wide variety of non-alcoholic and
alcoholic beverages containing natural and organic
ingredients.
|
|
● |
Dietary Supplements. We offer a wide selection of vitamins,
supplements and natural remedies. Our staff is well educated and
trained on multiple aspects of natural medicine.
|
|
● |
Health, Beauty, and Personal Care. We offer a full range of
cosmetics, skin care, hair care, fragrance and personal care
products containing natural and organic ingredients. Our body care
offerings range from bargain-priced basics to high-end
formulations.
|
|
● |
Household and General Merchandise. Our offerings include
sustainable, hypo-allergenic and fragrance-free household products,
including cleaning supplies, paper products, dish and laundry soap
and other common household products, including diapers.
|
Quality Assurance. We endeavor to ensure the quality of the
products we sell. We work with reputable suppliers we believe are
compliant with established regulatory and industry guidelines. Our
purchasing department requires a complete supplier and product
profile as part of the approval process. Our dietary supplement
suppliers must follow Food and Drug Administration (FDA) current
good manufacturing practices supported by quality assurance testing
for both the base ingredients and the finished product. We expect
our suppliers to comply with industry best practices for food
safety.
Many of our suppliers are inspected and certified under the USDA
National Organic Program, voluntary industry associations, and
other third-party auditing programs with regards to additional
ingredients, manufacturing and handling standards. We operate all
our stores in compliance with the National Organic Program
standards, which restricts the use of certain substances for
cleaning and pest control and requires rigorous recordkeeping,
among other requirements.
Our Pricing Strategy
We believe our pricing strategy allows our customers to shop our
stores on a regular basis for their groceries and dietary
supplements.
The key elements of our pricing strategy include:
|
● |
heavily advertised discounts supported by manufacturer
participation;
|
|
● |
in-store specials generally lasting for 30 days and not advertised
outside the store;
|
|
● |
managers’ specials, such as clearance, overstock, short-dated or
promotional incentives; and
|
|
● |
specials on seasonally harvested produce.
|
As we expand our store base, we believe there are opportunities for
increased leverage in fixed costs, such as administrative expenses,
as well as increased economies of scale in sourcing products. We
strive to keep our product, operating and general and
administrative costs low, which allows us to continue to offer
attractive pricing for our customers.
Store Management and Staffing. Our store staffing includes a
manager and assistant manager, with department managers in each of
the dietary supplement, grocery, dairy and frozen, produce, body
care and receiving departments, as well as several non-management
employees. Our regional manager is responsible for monthly store
profit and loss, including labor, merchandising and inventory
costs.
To ensure a high level of service, all employees receive training
and guidance on customer service skills, product attributes and
nutrition education. Employees are carefully trained and evaluated
based on a requirement that they present nutrition information in
an appropriate and legally compliant educational context while
interacting with customers. Additionally, store employees are
cross-trained in various functions, including cashier duties,
stocking and receiving product.
Inventory. We use a robust merchandise management and
perpetual inventory system that values goods at average cost. We
manage shelf stock based on weeks-on-hand relative to sales,
resupply time and minimum economic order quantity.
Sourcing and Vendors. We source from approximately 460
suppliers, and offer over 4,000 brands. These suppliers range from
small independent businesses to multi-national conglomerates. As of
December 31, 2021, we purchased approximately 69% of the goods we
sell from our top 20 suppliers. For the year ended 2021,
approximately 25% of our total purchases were from one vendor. We
maintain good relations with all our suppliers and believe we have
adequate alternative supply methods, including
self-distribution.
We have longstanding relationships with our suppliers, and we
require disclosure from them regarding quality, freshness, potency
and safety data information. Our bulk food private label products
are packaged by us in pre-packed sealed bags to help prevent
contamination while in transit and in our stores. Unlike most of
our competitors, most of our private label nuts, trail mix and
flours are refrigerated in our warehouse and stores to maintain
freshness.
Our Employees
Commitment to our employees is one of our founding principles.
Employees are eligible for health, long-term disability, vision and
dental insurance coverage, as well as Company paid short-term
disability and life insurance benefits, after they meet eligibility
requirements. Additionally, our employees are offered a 401(k)
retirement savings plan with discretionary contribution matching
opportunities. This further offers our employees the opportunity to
become more familiar with our products, which we believe improves
the customer service our employees are able to provide. We believe
these and other factors result in higher retention rates and
encourage our employees to appreciate our culture, which helps them
better promote our brand.
Our Customers
The growth in the natural and organic grocery and dietary
supplement industries and growing consumer interest in health and
nutrition have led to an increase in our core customer base. We
believe the demands for affordable, nutritious food and dietary
supplements are shared attributes of our core customers, regardless
of their socio-economic status. Additionally, we believe our core
customers prefer a retail store environment that offers carefully
selected natural and organic products and dietary supplements. Our
customers tend to be interested in health and nutrition, and expect
our store employees to be highly knowledgeable about these topics
and related products.
Competition
The
grocery and dietary supplement retail business is a large,
fragmented and highly competitive industry, with few barriers to
entry. Our competition varies by market and includes conventional
supermarkets such as Publix and Winn-Dixie, mass or discount
retailers such as Sprout's Farmers Market, Wal-Mart and Target,
natural and gourmet markets such as Whole Foods and The Fresh
Market, specialty food retailers such as Trader Joe’s, independent
health food stores, dietary supplement retailers, drug stores,
farmers’ markets, food co-ops, mail order and online retailers and
multi-level marketers. These businesses compete with us for
customers on the basis of price, selection, quality, customer
service, shopping experience or any combination of these or other
factors. They also compete with us for products and locations. In
addition, some of our competitors are expanding to offer a greater
range of natural and organic foods. We believe our commitment to
carrying only carefully vetted, affordably priced and high-quality
natural and organic products and dietary supplements, as well as
our focus on providing nutritional education, differentiate us in
the industry and provide a competitive advantage.
The Grocery business and COVID-19
The COVID-19 pandemic had little impact on the grocery segment of
the business, other than the Green Leaf Grill. Demand for
groceries, vitamins and supplements, and household products
remained strong. However, due to many local businesses
temporarily closing and local dinning restrictions, the Green Leaf
Grill located at Ada's Natural Market was forced to reduce hours
for most of 2020 and 2021.
To address the impact of the virus, we have instituted strict
cleaning protocols at all locations, provided PPE equipment for all
employees and offered online ordering and curbside pick-up for all
customers preferring to not enter the store.
HEALTHY CHOICE WELLNESS CENTERS
Healthier choices extend past just healthy eating. HCMC, through
its Healthy Choice Wellness Centers, offers premium and optimized
whole person-centered care and services, tailored to promote and
maximize one's general health and well-being. Healthy Choice
Wellness Centers’ services are designed to address one or more
common concerns, including but not limited to immunity, anxiety,
mental fortitude, sports recovery, and more. Through these
services, which include IV Nutrient Drip Infusions and
Intramuscular (IM) Injection Treatments, Healthy Choice Wellness
Centers seek to provide healthy alternatives that treat the mind
and body to its core, thus offering optimized healthier
living.
Defining Healthy Choice Wellness
o
|
indicative of, conducive to, or promoting good health
|
o
|
an act of selecting or making a decision when faced with two or
more possibilities
|
o
|
the state of being in good health, especially as an actively
pursued goal
|
Our Mission
•
|
To assist in one's achievement of personal well-being, which is an
optimal and dynamic state that allows people to achieve their full
potential through both the individual pursuit of wellness and the
commitment and support of the communities to which they
belong.
|
•
|
To assist in maximizing overall individual wellness, which is an
active process that helps individuals reach their optimal
well-being by integrating all the dimensions of wellness into their
lives; physical, social, emotional, spiritual, environmental,
intellectual, occupational, and financial.
|
•
|
To provide the highest standards of professionalism, emphasizing on
quality of care, ethical behavior, ensuring client confidentiality,
and the treatment of all individuals with respect and
dignity.
|
•
|
To provide clients an immaculate wellness facility designed for the
optimal benefit of the clients to receive their desired treatments
in a clean and sterile environment that fosters a tranquil space to
maximize one's overall wellness and well-being.
|
•
|
To continue the powerful pursuit of knowledge and education by all
of our professionals and practitioners, to better provide consult
to our clients for them to best maximize their overall wellness and
well-being.
|
Our Vision
Life comes with a lot of choices - some easier to make than others.
Healthier Living should be the easiest of those choices, and so
Healthy Choice Wellness Centers offers Health & Wellness
services that assist in making those choices a lot easier. Healthy
Choice Wellness Centers seek to continue the commitment of its
parent company, Healthier Choices Management Corp., in providing
consumers with healthier alternatives to everyday lifestyle
choices.
Healthy Choice Wellness Centers offer premium and optimized whole
person-centered care and services, tailored to promote and maximize
one's general health and well-being. All of our services are
designed to address one or more common concerns, including but not
limited to immunity, anxiety, mental fortitude, sports recovery,
and more. Through these services, Healthy Choice Wellness Centers
seek to provide healthy alternatives that treat the mind and body
to its core, thus offering optimized healthier living.
Our Values
Healthy Choice Wellness Centers are committed to building a culture
of well-being. Our goal is to optimize wellness, both for today and
all of our tomorrows.
Healthy Choice Wellness Centers view the communities we serve as
being comprised of whole and dynamic individuals. We are sensitive
to the communal stresses of life that impact our health, wellness,
and overall well-being. We promote and encourage personal
responsibility and accountability in one's pursuit of achieving and
maintaining their health and wellness. Our Healthy Choice Wellness
team not only participates in the facilitation of services in the
process of achieving one's wellness, but also are present to
provide information, care, and knowledge to maintain course and
maximize one's well-being according to their individual health
goals, wants, and needs.
Healthy Choice Wellness Center also realizes that the whole is only
as strong as its parts when it comes to those communities we serve.
Thus, we put forth effort to strengthen the environments in which
we live and work as they directly impact our well-being. This
effort to support wellness for the individuals (the parts) must
include working to create a healthy community at large (the whole)
that supports the well-being of its members at large.
Our Growth Strategy
We seek to operate and expand our Healthy Choice Wellness centers
by approaching growth via three (3) different pathways:
1)
|
Corporately owned and operated wellness centers
|
2)
|
Wellness Centers implementing the services of Healthy Choice
Wellness Centers by way of licensing agreements
|
3)
|
Expansion by way of franchised locations
|
Our Products & Services
Healthy Choice Wellness Centers specialize primarily in IV Nutrient
Drip Infusion and Intramuscular (IM) Injection treatments, however
we seek to expand these offerings (both in the number of IV and IM
options offered, but also by adding additional whole-person
centered services for optimizing overall general health).
IV Nutrient Drip Infusion Treatments: Healthy
Choice Wellness Center’s IV Nutrient Drip Infusions are used to
deliver vitamins and minerals directly into the bloodstream,
offering superior absorption over oral supplements. We offer server
pre-formulated customized solutions to address a variety of issues
including:
•
|
Immune System Strengthening
|
•
|
Optimal Athletic Performance & Recovery
|
•
|
Hangover & Headache Relief
|
Currently, we offer eleven IV Nutrient Treatment Options: Quench,
Get-Up-And-Go, Recovery & Performance, Immunity, Alleviate,
Inner Beauty, Myers’ Cocktail, Nad+ (Premium Drip), Reboot,
Glutathion, and Brainstorm.
Intramuscular (IM) Injection Treatments: Healthy
Choice Wellness Center’s Intramuscular (IM) Injection treatments
deliver vitamins and minerals directly into the bloodstream,
offering superior absorption over oral supplements. We offer server
pre-formulated customized solutions to address a variety of issues
including:
Currently we offer four Injection Treatment Options: Vitamin B-12,
Vitamin D-3, Glutathione, and our Skinny Shot.
Our Employees
Each Healthy Choice Wellness Center is led by licensed and
accredited medical professionals and practitioners who share a
like-minded philosophy with that of the Wellness Centers, as does
all our support staff – we do not just practice healthy choices, we
live it! We encourage and support all of our professionals and
practitioners to continue the powerful pursuit of knowledge and
education, to better provide consult to our clients for them to
best maximize their overall wellness and well-being.
Our Customers
The client base for our wellness centers is not bound by age groups
or genders. Our clients consist of a broad range of individuals all
seeking a common universal goal of seeking to improve their overall
wellness. These individuals tend to be those who consciously
live a healthy lifestyle, and are seeking treatments to maximize
and optimize their overall well-being. This includes athletes
seeking treatments to help recover quicker from injury and/or
rehydrate, middle aged men and women seeking treatments to maximize
their cognitive fortitude, those wanting to help alleviate
indigestion or stomach pains, and a slew of other individual
reasons all ending with the drive for healthier living.
ONLINE SALES
HCMC is your online source for the leading products in the
all-natural vitamin and supplement, and health, beauty, and
personal care categories of Healthier Living.
Backed by 30+ years of combined experience in the health and
nutrition industry, we provide our customers with only the best
products on the market — Try our exclusive offering of Ada’s
Naturals brand products or any of the top products from the most
recognized national natural health brands in the industry.
|
● |
VITAMINS & SUPPLEMENTS:
|
o
|
Product categories include, but are not limited to: Vitamins,
Minerals & Herbals, Immunity, Multivitamins, Sports Nutrition,
Protein Powders, Collagen, Stress & Anxiety, Sleep & Relax,
Brain Health, Pain & Inflammation, Probiotics, Energy &
Stamina, Joint & Bone Support, Digestion, Fish Oils, Just for
Men, Kids/Children/Teens, and more.
|
o
|
Product varieties include, but are not limited to: Apple Cider
Vinegar, BCAA, Biotin, Calcium, Chlorophyll, CLA, Collagen
Peptides, Creatine, Elderberry, Omega-3’s, Garlin, Glucosamine,
Iron, Magnesium, Melatonin, Potassium, Prenatals, Probiotics,
Protein Powders (Plant and Whey), Ashwaghanda Turmeric, Ginseng,
Vitamin B,C,D,E,K+, Zinc, and more.
|
o
|
Product brands include, but are not limited to: Ada’s Naturals,
Enzymedica, Garden of Life, Natural Vitality, New Chapter, Renew
Life, Solgar, and more.
|
|
● |
HEALTH, BEAUTY, AND PERSONAL CARE:
|
o
|
Product categories include, but are not limited to: Oral Care, Hair
Care, Body Wash, Skin & Face, Deodorant, Suncare, Soaps,
Shaving, Feminine Hygiene, Lip Balms, Ear Candles, Lotions, Hand
Sanitizers, Essential Oils, and more.
|
o
|
Product varieties include, but are not limited to: Body Wash,
Deodorant, Ear Candles, Shampoos, Conditioners, Toothpaste,
Mouthwashes, Shaving, Bar Soaps, Liquid Soaps, Suncare, and
more.
|
o
|
Product brands include, but are not limited to: Ada’s Naturals,
Alba Botanica, Aura Cacia, Derma-E, Desert Essence, Dr. Bronners,
Every Man Jack, Heritage Store, Himalaya Botanique, Life-Flo, Lily
of the Desert, Natracare, Naturally Fresh, Oral Essentials, South
of France, Tea Tree Therapy, Thai Deodorant Stone, Thayers, and
more.
|
VAPORIZER BUSINESS
Retail Stores
While evaluating retail store operations in 2021, management
decided to decrease the inventory levels on hand for all of its
vape stores, due to a major decrease in foot traffic or temporary
closure of some stores a result of the COVID-19 pandemic.
Vaporizers
“Vaporizers” are battery-powered products that enable users to
inhale nicotine vapor. Regardless of their construction, they are
comprised of three functional components:
|
● |
a
mouthpiece, which is a small plastic cartridge that contains a
liquid nicotine solution;
|
|
● |
the heating element that vaporizes the liquid nicotine so that it
can be inhaled; and
|
|
● |
the electronic devices which include: a lithium-ion battery, an
airflow sensor, a microchip controller and an LED, which
illuminates to indicate use.
|
When a user draws air through the vaporizer, the air flow is
detected by a sensor, which activates a heating element that
vaporizes the solution stored in the mouthpiece/cartridge, the
solution is then vaporized and it is this vapor that is inhaled by
the user. The cartridge contains either a nicotine solution or a
nicotine free solution, either of which may be flavored.
Vaporizers feature a tank or chamber, a heating element and a
battery. The vaporizer user fills the tank with e-liquid or the
chamber with dry herb or leaf. The vaporizer battery can be
recharged and the tank and chamber can be refilled.
Our Brands
We sell a wide variety of our e-liquid under the Vape Store brand.
Our in-house engineering and graphic design teams work to provide
aesthetically pleasing, technologically advanced and affordable
vaporizer and e-liquid flavor options. We are in the process of
preparing to commercialize additional brands which we intend to
market to new customers and demographics.
Our Improvements and Product Development on Intellectual
Property
We have developed, trademarked and are preparing to commercialize
additional products. We include product development expenses as
part of our operating expenses. In October 2018, we announced the
granting of three US patents related to our Q-Cup™ technology. This
Q-Cup™ technology provides microdosing potentially more efficiency
depending on the vaping method and an “on the go” solution for
consumers who prefer to vape concentrates either medicinally or
recreationally. In addition, we have a suite of patent applications
pending in the United States. There is no assurance that we will be
awarded patents for of any of these pending patent
applications.
The Market for Vaporizers
We market our vaporizers as an alternative to traditional tobacco
cigarettes and cigars. We offer our products in multiple nicotine
strengths and flavors.
Distribution and Sales
The Company sells directly to consumers through the Company owned
retail vape stores. Our management believes that consumers are
shifting towards vape stores for an enhanced experience. This
enhanced experienced is derived from the greater variety of
products at the stores, the knowledgeable staff and the social
atmosphere. The Company anticipates an even smaller portion of
future revenue will continue to come from its retail stores as
underperforming stores are being closed.
Business Strategy
We believe and are seeing in our current stores that there is a
large consumer demand centered on vaporizer products and the
“atmosphere” created by the vape stores. We believe that our
reputation and our experience in the vaporizer industry, from a
development, customer service and production perspective, give us
an advantage in attracting customers.
Moreover, we believe that our history with our suppliers, including
the volume of products we source, gives us an advantage over other
market participants as it relates to favorable pricing, priority as
to inventory supply and delivery and first access to new products,
including first access to next generation products and
technology.
Competition
Competition in the vaporizer and e-liquid industry is intense. We
compete with other sellers of vaporizes, most notably Altria Group,
Inc., JT International, Imperial Tobacco, and Reynolds American,
Inc., which are big tobacco companies that have vaporizer and
electronic cigarette business segments. The nature of our
competitors is varied as the market is highly fragmented and the
barriers to entry into the business are low. Our direct competitors
sell products that are substantially similar to ours excluding any
products which we hold patents. As a general matter, we have access
to market and sell the similar vaporizers as our competitors and we
sell our products at substantially similar prices as our
competitors; accordingly, the key competitive factors for our
success is the quality of service we offer our customers, the scope
and effectiveness of our marketing efforts, including media
advertising campaigns and, increasingly, the ability to identify
and develop new sources of customers.
As discussed above, we compete against “big tobacco”, U.S.
cigarette manufacturers of both conventional tobacco cigarettes and
electronic cigarettes like Altria Group, Inc., JT International,
Imperial Tobacco, and Reynolds American, Inc. We compete against
“big tobacco” who offers not only conventional tobacco cigarettes
and electronic cigarettes and vaporizers, but also smokeless
tobacco products such as “snus” (a form of moist ground smokeless
tobacco that is usually sold in sachet form that resembles small
tea bags), chewing tobacco and snuff. “Big tobacco” has nearly
limitless resources, global distribution networks in place and a
customer base that is fiercely loyal to their brands. Furthermore,
we believe that “big tobacco” is devoting more attention and
resources to developing, acquiring technology patents, and offering
electronic cigarettes, vaporizers and e-liquids as these markets
grow. Because of their well-established sales and distribution
channels, marketing expertise and significant resources, “big
tobacco” is better positioned than small competitors like us to
capture a larger share of the electronic cigarette market. We also
compete against numerous other smaller manufacturers or importers
of cigarettes. There can be no assurance that we will be able to
compete successfully against any of our competitors, some of whom
have far greater resources, capital, experience, market
penetration, sales and distribution channels than us. If our major
competitors were, for example, to significantly increase the level
of price discounts offered to consumers, we could respond by
offering price discounts, which could have a materially adverse
effect on our business, results of operations and financial
condition.
Manufacturing
We have no manufacturing capabilities and do not intend to develop
any manufacturing capabilities. Third party manufacturers make our
products to meet our design specifications. We depend on third
party manufacturers for our vaporizer e-liquid and accessories. Our
customers associate certain characteristics of our products
including the weight, feel, draw, unique flavor, packaging and
other attributes of our products to the brands we market,
distribute and sell. Any interruption in supply and or consistency
of our products may harm our relationships and reputation with
customers, and have a material adverse effect on our business,
results of operations and financial condition. In order to minimize
the risk of supply interruption, we currently utilize several
third-party manufacturers to manufacture our products to our
specifications.
We currently utilize several manufacturers both domestically and
internationally. We contract with our manufacturers on a purchase
order basis. We do not have any output or requirements contracts
with any of our manufacturers. Our manufacturers provide us with
finished products, which we hold in inventory for distribution,
sale and use.
Patent Litigation
Third party patent lawsuits alleging our infringement of patents,
trade secrets or other intellectual property rights have and could
force us to do one or more of the following:
|
● |
stop selling products or using technology that contains the
allegedly infringing intellectual property;
|
|
● |
incur significant legal expenses;
|
|
● |
pay substantial damages to the party whose intellectual property
rights we may be found to be infringing;
|
|
● |
redesign those products that contain the allegedly infringing
intellectual property; or
|
|
● |
attempt to obtain a license to the relevant intellectual property
from third parties, which may not be available to us on reasonable
terms or at all.
|
Future third party lawsuits alleging our infringement of patents,
trade secrets or other intellectual property rights could have a
material adverse effect on our business, results of operations and
financial condition.
We are required to obtain licenses to patents or proprietary rights
of others and may be required to obtain more in the future and as
the product continues to evolve. We cannot assure you that any
future licenses required under any such patents or proprietary
rights would be made available on terms acceptable to us or at all.
If we do not obtain such licenses, we could encounter delays in
product market introductions while we attempt to design around such
patents, or could find that the development, manufacture, or sale
of products requiring such licenses could be foreclosed. Litigation
may be necessary to defend against claims of infringement asserted
against us by others, or assert claims of infringement to enforce
patents issued to us or exclusively licensed to us, to protect
trade secrets or know-how possessed by us, or to determine the
scope and validity of the proprietary rights of others. In
addition, we may become involved in oppositions in foreign
jurisdictions, reexamination declared by the United States Patent
and Trademark Office, or interference proceedings declared by the
United States Patent and Trademark Office to determine the priority
of inventions with respect to our patent applications or those of
our licensors. Litigation, opposition, reexamination or
interference proceedings could result in substantial costs to and
diversion of effort by us, and may have a material adverse impact
on us. In addition, we cannot assure you that our efforts to
maintain or defend our patents will be successful.
Patent Enforcement
On November 30, 2020, the Company filed a patent infringement
lawsuit against Philip Morris USA, Inc. and Philip Morris Products
S.A. in the U.S. District Court (“District Court”) for the Northern
District of Georgia (the “Complaint”). The lawsuit alleged
infringement on HCMC-owned patent(s) by the Philip Morris product
known and marketed as “IQOS™.” Philip Morris claims that it
is currently approaching 14 million users of its IQOS® product and
has reportedly invested over $3 billion in their smokeless tobacco
products. On December 3, 2021, the District Court effectively
dismissed HCMC’s patent infringement action against Philip Morris
USA, Inc. and Philip Morris Products S.A. On December 14,
2021, the Company filed an appeal of the District Court’s dismissal
of the Company’s patent infringement action against Philip Morris
USA, Inc. and Philip Morris Products S.A. HCMC believes the
District Court committed legal error by dismissing its complaint
for patent infringement and also by denying the Company’s motion to
amend its pleading.
Regulations
Since a 2010 U.S. Court of Appeals decision, the Food and Drug
Administration (“FDA”) is permitted to regulate electronic
cigarettes as “tobacco products” under the Family Smoking
Prevention and the Tobacco Control Act. Under this decision, the
FDA is not permitted to regulate electronic cigarettes as “drugs”
or “devices” or a “combination product” under the Federal Food,
Drug and Cosmetic Act unless they are marketed for therapeutic
purposes. This is contrary to anti-smoking devices like nicotine
patches, which undergo more extensive FDA regulation. Because the
Company does not market its electronic cigarettes for therapeutic
purposes, the Company’s electronic cigarettes are subject to being
classified as “tobacco products” under the Tobacco Control Act. The
Tobacco Control Act grants the FDA broad authority over the
manufacture, sale, marketing and packaging of tobacco products,
although the FDA is prohibited from issuing regulations banning all
cigarettes or all smokeless tobacco products, or requiring the
reduction of nicotine yields of a tobacco product to zero.
On September 9, 2020 the FDA began enforcing rules
that extended its regulatory authority to electronic cigarettes and
certain other tobacco products under the Tobacco Control Act. The
rules required that electronic cigarette and e-liquid manufacturers
(i) register with the FDA and report electronic cigarette products
and ingredient listings; (ii) market new electronic cigarette
products only after FDA review; (iii) only make direct and implied
claims of reduced risk if the FDA confirms that scientific evidence
supports the claim and that marketing the electronic cigarette
product will benefit public health as a whole; (iv) not distribute
free samples; (v) implement minimum age and identification
restrictions to prevent sales to individuals under age 21; (vi)
include a health warning; and (vii) not sell electronic cigarettes
in vending machines, unless in a facility that never admits youth.
It is not known how long finalizing and implementing this
regulatory process may take. Accordingly, the Company has responded
by beginning to take the necessary steps to ensure
compliance.
In this regard, total compliance and related costs are not possible
to predict and depend substantially on the future requirements
imposed by the FDA under the Tobacco Control Act. Costs, however,
could be substantial and could have a material adverse effect on
the Company’s business, results of operations and financial
condition. In addition, failure to comply with the Tobacco Control
Act and with FDA regulatory requirements could result in
significant financial penalties and could have a material adverse
effect on the Company’s business, financial condition and results
of operations and ability to market and sell the Company’s
products. At present, it is difficult to predict whether the
Tobacco Control Act will impact the Company to a greater degree
than competitors in the industry, thus affecting the Company’s
competitive position.
State and local governments currently legislate and regulate
tobacco products, including what is considered a tobacco product,
how tobacco taxes are calculated and collected, to whom and by whom
tobacco products can be sold and where tobacco products may or may
not be smoked. State and local regulation of the e-cigarette market
and the usage of e-cigarettes is beginning to accelerate.
As local regulations expand, vaporizers and electronic cigarettes
may lose their appeal as an alternative to cigarettes, which may
have the effect of reducing the demand for the Company’s products
and as a result have a material adverse effect on the Company’s
business, results of operations and financial condition.
At present, neither the Prevent All Cigarette Trafficking Act
(which prohibits the use of the U.S. Postal Service to mail most
tobacco products, which would require individuals and businesses
that make interstate sales of cigarettes or smokeless tobacco to
comply with state tax laws) nor the Federal Cigarette Labeling and
Advertising Act (which governs how cigarettes can be advertised and
marketed) apply to electronic cigarettes. The application of either
or both of these federal laws to vaporizers and electronic
cigarettes would have a material adverse effect on the Company’s
business, results of operations and financial condition.
On July 1, 2015, the FDA published a document entitled “Advanced
notice of proposed rulemaking” or the Advance. Through the Advance,
the FDA solicited public comments on whether it should issue rules
with respect to nicotine exposure warning and child-resistant
packaging for e-liquids containing nicotine. Following public
comment, the FDA may issue proposed rules in furtherance of the
purposes outlined in the Advance and ultimately pass the rules as
proposed or in modified form. We cannot predict whether rules will
be passed or if they will have a material adverse effect on our
future results of operations and financial conditions.
The Company expects that the tobacco industry will experience
significant regulatory developments over the next few years, driven
principally by the World Health Organization’s FCTC. The FCTC is
the first international public health treaty on tobacco, and its
objective is to establish a global agenda for tobacco regulation
with the purpose of reducing initiation of tobacco use and
encouraging cessation. Regulatory initiatives that have been
proposed, introduced or enacted include:
|
● |
the levying of substantial and increasing tax and duty
charges;
|
|
● |
restrictions or bans on advertising, marketing and
sponsorship;
|
|
● |
the display of larger health warnings, graphic health warnings and
other labelling requirements;
|
|
● |
restrictions on packaging design, including the use of colors and
generic packaging;
|
|
● |
restrictions or bans on the display of tobacco product packaging at
the point of sale, and restrictions or bans on cigarette vending
machines;
|
|
● |
requirements regarding testing, disclosure and performance
standards for tar, nicotine, carbon monoxide and other smoke
constituents’ levels;
|
|
● |
requirements regarding testing, disclosure and use of tobacco
product ingredients;
|
|
● |
increased restrictions on smoking in public and work places and, in
some instances, in private places and outdoors;
|
|
● |
elimination of duty free allowances for travelers; and
|
|
● |
encouraging litigation against tobacco companies.
|
If Vaporizers, electronic cigarettes, or e-liquids, are subject to
one or more significant regulatory initiates enacted under the
FCTC, the Company’s business, results of operations and financial
condition could be materially and adversely affected.
Seasonality
Our business is active throughout the calendar year and does not
experience significant fluctuation caused by seasonal changes in
consumer purchasing.
The Vape Business and COVID-19
The COVID-19 pandemic had moderate to significant impact on the
vape business depending on the location of the retail store.
Several stores, located in smaller towns, saw a greater negative
impact than stores located in larger retail environments. As
stores reopened and retail consumers re-emerged, operations at all
locations have stabilized.
To address the impact of the virus, we have instituted strict
cleaning protocols at all locations, provided PPP equipment for all
employees and offered curbside pick-up for all customers preferring
to not enter the store.
Insurance and Risk Management
We use a combination of insurance and self-insurance to cover
workers’ compensation, general liability, product liability,
director and officers’ liability, employment practices liability,
associate healthcare benefits and other casualty and property
risks. Changes in legal trends and interpretations, variability in
inflation rates, changes in the nature and method of claims
settlement, benefit level changes due to changes in applicable
laws, insolvency of insurance carriers and changes in discount
rates could all affect ultimate settlements of claims. We evaluate
our insurance requirements and providers on an ongoing basis.
Information Technology Systems
We have made significant investments in overhead and information
technology infrastructure, including purchasing, receiving,
inventory, point of sale, warehousing, distribution, accounting,
reporting and financial systems.
Segment Information
We have two reporting segments, natural and organic retail stores
(“Grocery”) and vapor products (“Vapor”), through which we conduct
all of our business.
The Company has included the results of the Healthy
Choice Wellness Centers under the grocery segment due to its
sales being de minimis.
Going Concern and Liquidity
The accompanying consolidated financial statements have been
prepared in conformity with accounting principles generally
accepted in the United States of America (“GAAP”), which
contemplate the continuation of the Company as a going concern for
the next twelve months from the issuance of this Form 10-K and
realization of assets and satisfaction of liabilities in the normal
course of business and do not include any adjustments that might
result from the outcome of any uncertainties related to our going
concern assessment. The carrying amounts of assets and liabilities
presented in the consolidated financial statements do not
necessarily purport to represent realizable or settlement
values.
The Company currently and historically has reported net losses and
cash outflows from operations. As of December 31, 2021, cash and
cash equivalents totaled approximately $26.5 million. The Company
anticipates that its current cash, cash equivalent and cash
generated from operations will be sufficient to meet the projected
operating expenses for the foreseeable future through at least
twelve months from the issuance of these consolidated financial
statements.
Not applicable to smaller reporting companies.
Item 1B.
Unresolved Staff Comments.
None
The Company operates its business from numerous facilities in
Florida and New York. These leased facilities include our
headquarters location, warehouse and retail stores.
Grocery Segment. As of December 31, 2021, our Grocery segment had 4
retail stores in Florida which aggregate approximately 28,000
square feet, all of which are leased by our grocery segment.
Healthy
Choice Wellness Centers leases a facility in New York.
Vapor Segment. As of December 31, 2021, our Vapor segment operated
6 retail stores in Florida, aggregating approximately 8,000
square feet.
Our headquarters and warehouse are located in Hollywood, Florida
which aggregates approximately 10,000 square feet.
Item 3.
Legal Proceedings.
No response is required under Item 103 of Regulation S-K.
Item 4.
Mine Safety Disclosures.
None.
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.
Our common stock is currently listed on the OTC Pink marketplace
under the symbol “HCMC”.
As of March 31, 2022, there were approximately 1,400 stockholders
of record for our common stock. A substantially greater number of
stockholders may be “street name” or beneficial holders, whose
shares are held of record by banks, brokers and other financial
institutions.
As of March 31, 2022, the last reported sale price of our common
stock on the OTC Pink Marketplace was $0.0003 per share.
We have never declared or paid, and do not anticipate declaring or
paying, any cash dividends on any of our capital stock. We
currently intend to retain all available funds and any future
earnings for use in the operation of our business and do not
anticipate paying any dividends in the foreseeable future. Future
determination as to the declaration and payment of dividends, if
any, will be at the discretion of our Board and will depend on then
existing conditions, including our operating results, financial
conditions, contractual restrictions, capital requirements,
business prospects and other factors our Board may deem
relevant.
On February 7, 2021, the Company entered into a Securities Purchase
Agreement, pursuant to which the Company sold and issued 5,000
shares of its Series D Convertible Preferred Stock (the “Preferred
Stock”) to a single institutional, accredited investor for $1,000
per share or an aggregate subscription of $5,000,000. Subject to a
customary “9.99% Beneficial Ownership Limitation blocker,” the
Preferred Stock is currently convertible into 2,083,333,333.33
shares of the Company’s Common Stock at a conversion price of
$0.0024 per share, with such conversion price subject to adjustment
as set forth below and described in the Certificate of
Designation.
As of December 31, 2021, the Company has issued 6,562,500,000
shares of Company common stock in connection with the exercise
of 4,200 shares of the Series D Convertible Preferred
Stock at a conversion price of $0.00064 per share. The
conversion price for the exercise of the preferred stock was reset
to the 80% of the lowest daily volume-weighted
average price ("VWAP") during the 5 Trading Days
immediately preceding the Effective Date of August 11, 2021.
On June 18, 2021, the Company issued 27,046,800,310 shares of
common stock in connection with the Rights Offering at a
subscription price of $0.0010 per share, generating gross proceeds
of approximately $27.0 million.
Item 6. Selected Financial Data.
Not required for smaller reporting companies.
Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.
You should read the following discussion in conjunction with our
audited historical consolidated financial statements, which are
included elsewhere in this report. “Management’s Discussion and
Analysis of Financial Condition” and “Results of Operations”
contains forward-looking statements that reflect our plans,
estimates, and beliefs. Our actual results could differ materially
from those discussed in the forward-looking statements.
Cautionary Note Regarding Forward Looking Statements
This report includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. All
statements other than statements of historical facts contained in
this report, including statements regarding our future financial
position, liquidity, business strategy, plans and objectives of
management for future operations, are forward-looking
statements.
Forward-looking statements contained in this report include:
● Our
liquidity;
● Opportunities
for our business; and
● Growth
of our business.
The words “believe,” “may,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “could,” “target,” “potential,” “is
likely,” “expect,” and similar expressions, as they relate to us,
are intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs.
The results anticipated by any or all of these forward-looking
statements might not occur. Important factors, uncertainties and
risks that may cause actual results to differ materially from these
forward-looking statements are contained in the Risk Factors
contained herein. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise. For more information regarding
some of the ongoing risks and uncertainties of our business, see
the Risk Factors below.
Factors Affecting Our Performance
We believe the following factors affect our performance:
Retail: We believe the operating performance of our retail
stores will affect our revenue and financial performance. The
Company has (1) a total of [six] retail vape stores and (2) [four]
natural and organic groceries and dietary supplement stores located
in Florida, as well as two located in New York. The Company has
reduced the number of retail vape stores due to adverse industry
trends and increasing federal and state regulations that, if
implemented, may negatively impact future retail revenues.
Increased Competition:
Food retail is a large and competitive industry. Our competition
varies and includes national, regional, and local conventional
supermarkets, national superstores, alternative food retailers,
natural foods stores, smaller specialty stores, and farmers’
markets. In addition, we compete with restaurants and other dining
options in the food-at-home and food-away-from-home markets. The
opening and closing of competitive stores, as well as restaurants
and other dining options, in regions where we operate will affect
our results. In addition, changing consumer preferences with
respect to food choices and to dining out or at home can impact us.
We
also expect increased product supply and downward pressure on
prices to continue and impact our operating results in the
future.
Our Response to the COVID-19 Pandemic: We are proud to
provide our guests with high quality, fresh foods and restaurant
quality meals, delivered with impeccable service in an
exceptionally clean and well-stocked store. With the ongoing
COVID-19 pandemic, we continue to carefully monitor and adjust our
safety protocols while following public health guideline and local
ordinances. We have maintained many of the protocols established at
the beginning of the pandemic to keep our team members and guests
safe. The COVID-19 pandemic has presented many risks and challenges
that we must manage. While we have experienced many challenges,
including but not limited to, product shortages, staffing
difficulties, and evolving customer shopping behaviors, our focus
remains on both offering our customers a high quality service
experience and supporting our essential front-line team members.
Though we have successfully managed these challenges to date, our
operations and financial condition could still be negatively
affected by the COVID-19 pandemic and future developments, which
are highly uncertain and cannot be predicted.
Results of Operations
The following table sets forth our Consolidated Statements of
Operations for the years ended December 31, 2021 and 2020 which is
used in the following discussions of our results of
operations:
|
|
For the Year Ended December 31,
|
|
|
2021 to 2020
|
|
|
|
2021
|
|
|
2020
|
|
|
Change $
|
|
SALES:
|
|
|
|
|
|
|
|
|
|
Vapor sales, net
|
|
$
|
2,084,813
|
|
|
$
|
2,458,945
|
|
|
$
|
(374,132
|
)
|
Grocery sales, net
|
|
|
11,235,041
|
|
|
|
11,461,800
|
|
|
|
(226,759
|
)
|
Total Sales
|
|
|
13,319,854
|
|
|
|
13,920,745
|
|
|
|
(600,891
|
)
|
Cost of sales vapor
|
|
|
839,599
|
|
|
|
1,033,805
|
|
|
|
(194,206
|
)
|
Cost of sales grocery
|
|
|
7,187,701
|
|
|
|
7,109,719
|
|
|
|
77,982
|
|
GROSS PROFIT
|
|
|
5,292,554
|
|
|
|
5,777,221
|
|
|
|
(484,667
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
380,646
|
|
|
|
(380,646
|
)
|
Selling, general and administrative
|
|
|
10,033,048
|
|
|
|
8,844,947
|
|
|
|
1,188,101
|
|
Total operating expenses
|
|
|
10,033,048
|
|
|
|
9,225,593
|
|
|
|
807,455
|
|
Operating loss
|
|
|
(4,740,494
|
)
|
|
|
(3,448,372
|
)
|
|
|
(1,292,122
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSES):
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on debt settlements
|
|
|
767,930
|
|
|
|
-
|
|
|
|
767,930
|
|
Other expenses, net
|
|
|
(26
|
)
|
|
|
(100
|
)
|
|
|
74
|
|
Interest expense, net
|
|
|
(65,281
|
)
|
|
|
(272,651
|
)
|
|
|
207,370
|
|
Gain (loss) on investment
|
|
|
412
|
|
|
|
(1,269
|
)
|
|
|
1,681
|
|
Total other income (expense), net
|
|
|
703,035
|
|
|
|
(274,020
|
)
|
|
|
977,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
$
|
(4,037,459
|
)
|
|
$
|
(3,722,392
|
)
|
|
$
|
(315,067
|
)
|
Net
vapor sales decreased $0.4 million
to $2.1 million
for the year ended December 31, 2021 as
compared to $2.5 million
for the same period in 2020.
The decrease in sales was primarily due to a major decrease in foot
traffic and a decrease in the number of stores open compared to
prior year. Net grocery sales decreased $0.2
million
to $11.2 million
for the year ended December 31, 2021 as
compared to $11.5 million
for the same period in 2020.
The decrease in sales was primarily due to a decrease in the
customer count compared to prior year.
Vapor
cost of goods sold for the year ended December 31, 2021
and
2020 were
$0.8 million
and $1.0 million,
respectively, a decrease of $0.2 million.
The decrease in cost of goods sold was primarily due to a decreased
in sales and product cost. Grocery store cost of goods sold for the
year ended December 31, 2021 and
2020 were
$7.2 million
and $7.1 million,
respectively, an increase of $0.1 million primarily due to a
write-off of inventory.
Total
operating expenses increased $0.8 million
to $10.0 million
for the year ended December 31, 2021.
The increase was primarily due to an increase in professional fees
of $1.1 million and payroll benefits of $0.4 million,
partially offset by the impairment of goodwill and
intangible assets of $0.4 million in prior year.
Net
other income of $0.7 million
for the year ended December 31, 2021 includes
a gain on debt settlements of $0.8 million, partially offset by an
interest expense of $0.1 million. Net other expense of $0.3
million
for the year ended December 31, 2020 includes
primarily interest expense.
Liquidity and Capital Resources
|
|
For the year ended December 31,
|
|
|
|
2021
|
|
|
2020
|
|
Net cash provided by (used in):
|
|
|
|
|
|
|
Operating activities
|
|
$
|
(3,528,205
|
)
|
|
$
|
(2,281,797
|
)
|
Investing activities
|
|
|
(87,322
|
)
|
|
|
(75,202
|
)
|
Financing activities
|
|
|
27,186,456
|
|
|
|
1,771,293
|
|
|
|
$
|
23,570,929
|
|
|
$
|
(585,706
|
)
|
Our net cash used in operating activities of $3.5 million for the
year ended December 31, 2021 resulted from our net loss of $4.0
million and a net cash usage of $0.6 million from changes in
operating assets and liabilities, offset by a non-cash adjustments
of $1.0 million. Our net cash used in continuing operating
activities of $2.3 million for the year ended December 31, 2020
resulted from our net loss from continuing operations of $3.7
million, offset by a net cash usage of $0.5 million from changes in
operating assets and liabilities and a non-cash adjustments of $1.9
million.
The net cash used in investing activities of $0.1 million for the
year ended December 31, 2021 resulted
from the collection of a note receivable, the acquisition of new
business and purchases of a patent and property and
equipment. The net cash provided by investing activities of
$0.1 million for the year ended December 31, 2020 resulted from the
issuance and collection of a note receivable, and purchases of a
patent and property and equipment.
The net cash provided by financing activities of $27.2 million for
the year ended December 31, 2021 is due to proceeds received
from the Rights Offering of $24.3 million and a Securities
Purchase Agreement of $5.0 million, partially
offset by a principal payment of $2.0 million on the line of
credit. The net cash used in financing activities of $1.8
million for the year ended December 31, 2020 is due to proceeds
received from the Paycheck Protection Program of $0.9 million and
Term Loan of $2.5 million, partially offset by payments
of $1.7 million on the loan payable.
At December 31, 2021 and December 31, 2020, we did not have any
material financial guarantees or other contractual commitments with
trade vendors that are reasonably likely to have an adverse effect
on liquidity.
Our cash balances are kept liquid to support our growing
acquisition and infrastructure needs for operational expansion. The
majority of our cash and cash equivalents are concentrated in three
large financial institutions and are generally in excess of the
Federal Deposit Insurance Corporation (FDIC) insurance limit. The
Company has not experienced any losses on its cash and cash
equivalents. The following table presents the Company’s cash
position as of December 31, 2021 and December 31, 2020.
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
26,496,404
|
|
|
$
|
925,475
|
|
Total assets
|
|
$
|
34,443,487
|
|
|
$
|
11,874,993
|
|
Percentage of total assets
|
|
|
76.9
|
%
|
|
|
7.8
|
%
|
The Company reported net loss of approximately $4.0 million for the
year ended December 31, 2021. The Company also had positive working
capital of $26.2 million. The Company expects to continue incurring
losses for the foreseeable future and may need to raise additional
capital to satisfy business obligations, and to continue as a going
concern.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements other than
operating leases for retail locations, equipment, and
vehicles.
Seasonality
We do not consider our business to be seasonal.
Non-GAAP Financial Measures
The following discussion and analysis contains a non-GAAP financial
measure. Generally, a non-GAAP financial measure is a numerical
measure of a company’s performance, financial position or cash
flows that either excludes or includes amounts that are not
normally included or excluded in the most directly comparable
measure calculated and presented in accordance with generally
accepted accounting principles (GAAP). Non-GAAP financial measures
should be viewed as supplemental to, and should not be considered
as alternative to, net income, operating income, and cash flow from
operating activities, liquidity or any other financial measures.
Non-GAAP financial measures may not be indicative of the historical
operating results of the Company nor are they intended to be
predictive of potential future financial results. Investors should
not consider non-GAAP financial measures in isolation or as
substitutes for performance measures calculated in accordance with
GAAP.
Management believes stockholders benefit from referring to the
Adjusted EBITDA in planning, forecasting, and analyzing future
periods. Management uses this non-GAAP financial measure in
evaluating its financial and operational decision making and as a
means of evaluating period to period comparison.
We define Adjusted EBITDA as net loss from operations adjusted for
non-cash charges for depreciation and amortization and stock
compensation. Management believes Adjusted EBITDA is an important
measure of our operating performance because it allows management,
investors and analysts to evaluate and assess our core operating
results from period to period after removing the impact of
significant non-cash charges that effect comparability between
reporting periods. Our management recognizes that Adjusted EBITDA
has inherent limitations because of the excluded items.
We have included a reconciliation of our non-GAAP financial measure
to loss from operations as calculated in accordance with GAAP. We
believe that providing the non-GAAP financial measure, together
with the reconciliation to GAAP, helps investors make comparisons
between the Company and other companies. In making any comparisons
to other companies, investors need to be aware that companies use
different non-GAAP measures to evaluate their financial
performance. Investors should pay close attention to specific
definitions being used and to the reconciliation between such
measures and the corresponding GAAP measures provided by each
company under applicable rules of the Securities and Exchange
Commission.
|
|
2021
|
|
|
2020
|
|
Reconciliation of Adjusted EBITDA to net loss allocable to common
stockholders:
|
|
|
|
|
|
|
Operating loss
|
|
$
|
(4,740,494
|
)
|
|
$
|
(3,448,372
|
)
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
380,646
|
|
Depreciation and amortization
|
|
|
497,408
|
|
|
|
550,098
|
|
Stock-based compensation expense
|
|
|
34,375
|
|
|
|
78,029
|
|
Adjusted EBITDA
|
|
$
|
(4,208,711
|
)
|
|
$
|
(2,439,599
|
)
|
Item 7A. Quantitative and Qualitative Disclosures About Market
Risk.
Not applicable to smaller reporting companies.
Item 8. Financial Statements and Supplementary
Data.
See pages F-1 through F-23.
Item 9.
Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
None.
Item 9A.
Controls and Procedures.
We are required to report under Section 404(a) of Sarbanes-Oxley
regarding the effectiveness of our internal control over financial
reporting.
Evaluation of Disclosure Controls and Procedures. Our
management, including our Principal Executive Officer and Principal
Financial Officer, did not carry out an evaluation on internal
controls during the year ended December 31, 2021 in regard to the
effectiveness of our disclosure controls and procedures as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, or the Exchange Act. As an evaluation was not carried out,
our Principal Executive Officer and Principal Financial Officer
concluded that our disclosure controls and procedures were
ineffective as of the end of the period covered by this
report.
Management’s Annual Report on Internal Control over Financial
Reporting. Our management is responsible for
establishing and maintaining adequate internal controls over
financial reporting, as such term is defined in Rule 13a-15(f) of
the Securities Exchange Act of 1934. Our management, including our
Principal Executive Officer and Principal Financial Officer,
conducted an evaluation of the effectiveness of our internal
controls over financial reporting as of December 31, 2021.
In planning and performing its audit of our financial statements
for the year ended December 31, 2021 in accordance with standards
of the Public Company Accounting Oversight Board, our independent
registered public accounting firm noted material weaknesses in
internal control over financial reporting. A list of our material
weaknesses are as follows:
|
● |
Failure to have properly documented and designed disclosure
controls and procedures and testing of the operating effectiveness
of our internal control over financial reporting.
|
|
● |
Failure to perform periodic and year-end inventory observations in
a timely manner and adequate controls to sufficiently perform
required rollback procedures of inventory counts to the
year-end.
|
|
● |
Weakness around our purchase orders and inventory procedures,
inclusive of year-end physical inventory observation procedures as
well as physical count procedures.
|
|
● |
Segregation of duties due to lack of personnel.
|
Our management concluded that considering internal control
deficiencies that, in the aggregate, rise to the level of material
weaknesses, we did not maintain effective internal control over
financial reporting as of December 31, 2021 based on the criteria
set forth in Internal Control-Integrated Framework (2013) issued by
the Committee of Sponsoring Organizations of the Treadway
Commission (“COSO”).
Remediation
Efforts
Following this assessment and during the twelve months ended
December 31, 2021, we have undertaken an action plan to strengthen
internal controls and procedures:
|
● |
Management continues to devote significant efforts toward
improvement of effectiveness of control over financial reporting.
This includes analyzing non-routine transactions before booking
journal entries; implemented a monthly variance fluctuation
analysis across all segments. Variance analyses are communicated to
operations and executives to make sure the results are
accurate.
|
|
● |
Our management continues to remain focused on the
Company’s purchase order process in order to better manage
inventory thereby improving cash management and ultimately leading
to more reliable and precise financial reporting.
|
•
|
The Company is evaluating the addition of a new position, Inventory
Analyst, to handle all matters related to the implementation of a
cycle-count procedure as well as coordinating all physical
inventory counts with third parties.
|
|
● |
Vendor payments and cash disbursement are reviewed on weekly basis
by management and accounting team to ensure timely payment. Cash
balance are communicated to management on weekly basis to improve
cash management.
|
Our management continues to review ways in which we can make
improvements in internal control over financial reporting.
Item 9B.
Other Information.
None.
Item 10. Directors, Executive Officers and Corporate
Governance
Directors and Executive Officers
The following table sets forth information regarding our executive
officers and directors as of December 31, 2021:
Name
|
|
Age
|
|
Position
|
Executive Officers:
|
|
|
|
|
Jeffrey Holman
|
|
55
|
|
Chief Executive Officer, Chairman and Director
|
John A. Ollet
|
|
59
|
|
Chief Financial Officer
|
Christopher Santi
|
|
51
|
|
President and Chief Operating Officer
|
|
|
|
|
|
Non-Employee Directors:
|
|
|
|
|
Clifford J. Friedman
|
|
60
|
|
Director
|
Dr. Anthony Panariello
|
|
62
|
|
Director
|
Executive Officers
Jeffrey Holman has been our Chairman of the Board and Chief
Executive Officer since April 2014. From February 2013 until March
4, 2015, Mr. Holman serviced as our President. Mr. Holman has been
a member of our Board since May 2013 and has served as a member of
the Board of Directors of our subsidiary Smoke Anywhere, USA since
its inception on March 24, 2008. Since 1998, Mr. Holman has been
the President of Jeffrey E. Holman & Associates, P.A., a South
Florida based law firm. He has also been a Partner in the law firm
of Holman, Cohen & Valencia since 2000. Mr. Holman was selected
as a director for his business and legal experience. In addition,
as one of the founders of Smoke Anywhere, Mr. Holman possesses an
in-depth understanding of the challenges, risks and characteristics
unique to our industry.
Christopher Santi has been our Chief Operating Officer since
December 12, 2012 and has also served as the President since April
11, 2016. Previously, Mr. Santi served as Director of Operations of
the Company beginning in October 2011. Mr. Santi served as the
National Sales Manager of Collages.net from November 2007 to
October 2011.
John A. Ollet has been our Chief Financial Officer since
December 12, 2016. Mr. Ollet previously served as Executive Vice
President-Finance for Systemax, Inc. (NYSE:SYX) from 2006 to 2016.
His prior chief financial officer experience also includes serving
as Vice President and Chief Financial Officer of Arrow Cargo
Holdings, Inc., an airline logistics company, and VP Finance /CFO -
The Americas - Cargo Division, KLM Royal Dutch Airlines, an airline
company. He also previously served as Vice President
Finance/Administration at Sterling-Starr Maritime Group, Inc. and
served on the audit staff of Arthur Andersen & Co. Mr. Ollet
received a bachelor’s degree in Finance/Economics and a master’s
degree in business administration from Florida International
University. Mr. Ollet is a Certified Public Accountant.
Non-Employee Directors
Anthony Panariello, M.D.
has been a director since April 15, 2016. Dr. Panariello is a Board
Certified in Pulmonology and Internal Medicine in Florida and has
been in private practice since 1996, serving as an attending
physician at a number of hospitals. Dr. Panariello is a member of
the College of Physicians and the American College of Chest
Physicians. Additionally, Dr. Panariello currently serves as a
Lieutenant Commander in the Medical Corps of the United States Navy
Reserve. Dr. Panariello received his Bachelor of Science from the
State University of New York at Stony Brook and his medical degree
from the Autonomous University of Guadalajara.
Clifford J. Friedman has been a director since April 15,
2016. Mr. Friedman is a certified public accountant in Coral
Springs, Florida and manages his own public accounting, tax and
consulting practice since 2001. From 1992 to 2000, Mr. Friedman was
Vice President - Finance and Administration of the Box Worldwide,
Inc., a Viacom company. He received an M.B.A. from Nova
Southeastern University and his B.B.A. from Pace University.
Corporate Governance
Board Responsibilities
The Board oversees, counsels, and directs management in the
long-term interest of the Company and its stockholders. The Board’s
responsibilities include establishing broad corporate policies and
reviewing the overall performance of the Company. The Board is not,
however, involved in the operating details on a day-to-day
basis.
Board Committees and Charters
The Board and its Committees meet throughout the year and act by
written consent from time-to-time as appropriate. The Board
delegates various responsibilities and authority to different Board
Committees. Committees regularly report on their activities and
actions to the Board.
The Board currently has and appoints the members of: The Audit
Committee, the Compensation Committee and the Nominating and
Corporate Governance Committee. Each of these committees have a
written charter which can be found on our corporate website at
www.healthiercmc.com/committee-charters/.
The following table identifies the independent and non-independent
current Board and committee members:
Name
|
|
Independent
|
|
Audit
|
|
Compensation
|
|
Nominating And Corporate Governance
|
Jeffrey Holman
|
|
|
|
|
|
|
|
|
Dr. Anthony Panariello
|
|
X
|
|
X
|
|
X
|
|
X
|
Clifford J. Friedman
|
|
X
|
|
X
|
|
X
|
|
X
|
Director Independence
Our Board has determined that Clifford J. Friedman and Dr. Anthony
Panariello are independent in accordance with standards under the
OTC Pink Marketplace. Our Board determined that as a result of
being executive officer, Messrs. Jeffrey Holman is not independent
under the OTC Pink Marketplace Bulletin Boards. Our Board has also
determined that Clifford J. Friedman and Dr. Anthony Panariello are
independent under the OTC Pink Marketplace independence standards
for Audit and Compensation Committee members.
Committees of the Board
Audit Committee
The Audit Committee, which currently consists of Clifford J.
Friedman (chair) and Dr. Anthony Panariello, reviews the Company’s
financial reporting process on behalf of the Board and administers
our engagement of the independent registered public accounting
firm. The Audit Committee approves all audit and non-audit
services, and reviews the independence of our independent
registered public accounting firm.
Audit Committee Financial Expert
Our Board has determined that Clifford J. Friedman is qualified as
an Audit Committee Financial Expert, as that term is defined by the
rules of the SEC and in compliance with the Sarbanes-Oxley Act of
2002.
Compensation Committee
The function of the Compensation Committee is to determine the
compensation of our executive officers. The Compensation Committee
has the power to set performance targets for determining periodic
bonuses payable to executive officers and may review and make
recommendations with respect to stockholder proposals related to
compensation matters. Additionally, the Compensation Committee is
responsible for administering the Company’s equity compensation
plans including the Company’s 2015 Equity Incentive Plan, as
amended
The members of the Compensation Committee are all independent
directors within the meaning of applicable Nasdaq Listing Rules and
all of the members are “non-employee directors” within the meaning
of Rule 16b-3 under the Exchange Act.
Nominating and Corporate Governance Committee
The responsibilities of the Nominating and Corporate Governance
Committee include the identification of individuals qualified to
become Board members, the selection of nominees to stand for
election as directors, the oversight of the selection and
composition of committees of the Board, establish procedures for
the nomination process including procedures and the oversight of
the evaluations of the Board and management. The Nominating and
Corporate Governance Committee has not established a policy with
regard to the consideration of any candidates recommended by
stockholders since no stockholders have made any recommendations.
If we receive any stockholder recommended nominations, the
Nominating Committee will carefully review the recommendation(s)
and consider such recommendation(s) in good faith.
Compensation Committee Interlocks and Insider Participation
None of the members of our compensation committee has ever been an
officer or employee of the Company. None of our executive officers
serve, or have served during the last fiscal year, as a member of
our compensation committee or other Board committee performing
equivalent functions of any entity that has one or more executive
officers serving on our Board or on our compensation
committee.
Board Assessment of Risk
The Board is actively involved in the oversight of risks that could
affect the Company. This oversight is conducted primarily through
the Audit Committee, but the full Board has retained responsibility
for general oversight of risks. The Audit Committee considers and
reviews with our independent public accounting firm and management
the adequacy of our internal controls, including the processes for
identifying significant risks and exposures, and elicits
recommendations for the improvements of such procedures where
desirable. In addition to the Audit Committee’s role, the full
Board is involved in oversight and administration of risk and risk
management practices. Members of our senior management have
day-to-day responsibility for risk management and establishing risk
management practices, and members of management are expected to
report matters relating specifically to the Audit Committee
directly thereto, and to report all other matters directly to the
Board as a whole. Members of our senior management have an open
line of communication to the Board and have the discretion to raise
issues from time-to-time in any manner they deem appropriate, and
management’s reporting on issues relating to risk management
typically occurs through direct communication with directors or
committee members as matters requiring attention arise. Members of
our senior management regularly attend portions of the Board’s
meetings, and often discuss the risks related to our
business.
Presently, the largest risks affecting the Company are the
Company’s ability to manage and satisfy the Series A Warrant
obligations and evaluation of potential adverse impact of the FDA’s
final regulations on vaporizers and e-liquids on the retail
business operations. The Board actively interfaces with management
on seeking solutions.
Code of Ethics
The Company has a code of ethics, “Business Conduct: “Code of
Conduct and Policy,” that applies to all of the Company’s
employees, including its principal executive officer, principal
financial officer and principal accounting officer, and the Board.
A copy of this code is available on the Company’s website at
http://www.healthiercmc.com/code-of-conduct. The Company intends to
disclose any changes in or waivers from its code of ethics by
posting such information on its website or by filing a Current
Report on Form 8-K.
Stockholder Communications
Although we do not have a formal policy regarding communications
with our Board, stockholders may communicate with the Board by
writing to us at Healthier Choices Management Corp., 3800 N 28th
Way, Hollywood, FL 33020, Attention: Corporate Secretary, or by
facsimile (954) 272-7773. Stockholders who would like their
submission directed to a member of the Board may so specify, and
the communication will be forwarded, as appropriate.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our officers and
directors, and persons who own more than 10% of a registered class
of our equity securities, to file with the SEC initial reports of
ownership and reports of changes in ownership of common stock and
the other equity securities. Officers, directors and greater than
ten percent stockholders are required by SEC rules to furnish us
with copies of all Section 16(a) reports they file.
Based solely on a review of the reports furnished to us, or written
representations from reporting persons that all reportable
transactions were reported and that no Form 5s were required, we
believe that during 2021 our officers, directors and greater than
10% owners timely filed all reports they were required to file
under Section 16(a).
ITEM 11. Executive Compensation
The following information is related to the compensation paid,
distributed or accrued by us for fiscal 2021 to all Chief Executive
Officers (principal executive officers) serving during the last
fiscal year and the other most highly compensated executive
officers serving at the end of the last fiscal year whose
compensation exceeded $100,000. We refer to these individuals as
our “named executive officers.”
Summary Compensation Table
Name and Principal Position
|
Year
|
|
Salary ($)
|
|
|
Bonus ($)
|
|
|
Restricted Stock/ (Forfeited) (1)$
|
|
|
Restricted
Stock Awards(1)
$
|
|
|
All Other Compensation ($)
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jeffrey Holman
|
2021
|
|
|
578,579
|
|
|
|
250,000
|
|
|
|
(302,500
|
)
|
|
|
110,000
|
|
|
|
-
|
|
|
|
636,079
|
|
Chief Executive Officer
|
2020
|
|
|
494,430
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
494,430
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christopher Santi
|
2021
|
|
|
359,192
|
|
|
|
160,000
|
|
|
|
(220,000
|
)
|
|
|
80,000
|
|
|
|
-
|
|
|
|
379,192
|
|
President and Chief Operating Officer
|
2020
|
|
|
331,058
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
331,058
|
|
(1) Amounts
reflect the aggregate grant date fair value, without regard to
forfeitures, computed in accordance with ASC 718. These amounts
represent options and restricted stock of the Company’s common
stock and do not reflect the actual amounts that may be realized by
the Named Executive Officers. Our assumptions with respect to the
calculation of the stock options and restricted stock value are set
forth in Note 2 to the consolidated financial statements contained
herein.
Named Executive Officer Employment Agreements
On
August 13, 2018, the Company amended and restated its existing
employment agreement with Jeffrey Holman, the Company’s Chief
Executive Officer (the “Holman
Employment Agreement”).
The Holman Employment Agreement is for an additional three year
term and provides for an annual base salary of $450,000 and a
target bonus for 2020 only in an amount ranging from 20% to 200% of
his base salaries subject to the Company meeting certain earnings
before interest, taxes depreciation and amortization performance
milestones. Mr. Holman is entitled to receive severance payments,
including two years of his then base salary and other benefits in
the event of a change of control, termination by the Company
without cause, termination for good reason by the executive or
non-renewal by the Company. Mr. Holman was also granted 11 billion
shares of restricted common stock pursuant to the Holman Employment
Agreement Amendment on the condition that 11 billion of his options
to purchase Company common stock are forfeited. This restricted
stock will vest one year following the date of issuance provided
that the grantee remains an employee of the Company through each
applicable vesting date. On August 12, 2019, the Company agreed to
extend the expiration date of the vesting period for the restricted
stock by six months to February 13, 2020. On August 12, 2020, the
Company agreed to extend for a second time the expiration date of
the vesting period for the restricted stock by six months to
February 13, 2021. The Term shall be automatically renewed
for successive one-year terms unless notice of non-renewal is given
by either party at least 30 days before the end of the Term.
The
above description of the terms of the Holman Employment Agreement
is not complete and is qualified by reference to the complete
document.
On
February 26, 2021, the Company entered into an amended and restated
employment agreement (the “Employment
Agreement Amendment”)
with the Company’s President and Chief Operating Officer,
Christopher Santi. Pursuant to the Employment Agreement Amendment,
Mr. Santi will continue to be employed as the Company’s President
and Chief Operating Officer through January 30, 2024. Mr.
Santi will receive a base salary of $0.4 million for 2021 and
his salary will increase 10% in each subsequent year.
The Term shall be automatically renewed for successive one-year
terms unless notice of non-renewal is given by either party at
least 30 days before the end of the Term. The
above description of the terms of the Santi Employment Agreement is
not complete and is qualified by reference to the complete
document.
On
February 02, 2022, the Company entered into a second amended and
restated employment agreement (the “Employment
Agreement Amendment”)
with the Company’s Chief Financial Officer, John Ollet.
Pursuant to the Employment Agreement Amendment, Mr. Ollet will
continue to be employed as the Company’s Chief Financial Officer
through February 14, 2025. Mr. Ollet will receive a base
salary of $300,000 for 2022 and his salary will increase 10% in
each subsequent calendar year. The Term shall be
automatically renewed for successive one-year terms unless notice
of non-renewal is given by either party at least 30 days before the
end of the Term. The
above description of the terms of the Ollet Employment Agreement is
not complete and is qualified by reference to the complete
document.
Termination Provisions
The table below describes the severance payments that our Named
Executive Officers are entitled to in connection with a termination
of their employment upon death, disability, dismissal without
cause, Change of Control or for Good Reason. All of the termination
provisions are intended to comply with Section 409A of the Internal
Revenue Code of 1986 and the Regulations thereunder.
|
|
Holman
|
|
Santi/Ollet
|
Death or Total Disability
|
|
Any amounts due at time of termination plus full vesting of equity
awards
|
|
Any amounts due at time of termination
|
|
|
|
|
|
Dismissal Without Cause or Termination by Executive for Good Reason
or upon a Change of Control (1)
|
|
Two years of Base Salary, full vesting of equity awards, benefit
continuation for eighteen months plus pro-rated bonus if, any, that
would have been earned for the fiscal year in which the termination
occurs
|
|
Fifteen months of Base Salary plus one additional month for every
additional four months of service, up to eighteen months’
maximum
|
|
|
|
|
|
Termination upon a Change of Control (2)
|
|
Two years of Base Salary, full vesting of equity awards, benefit
continuation for eighteen months plus pro-rated bonus if, any, that
would have been earned for the fiscal year in which the termination
occurs
|
|
Eighteen months of Base Salary
|
(1) Good reason is generally (with certain exceptions) defined, in
the case of Holman, as (i) a material diminution in their
authority, duties or responsibilities, (y) the Company failing to
maintain an office in the stated area or (ii) any other action or
inaction that constitutes a material breach by the Company of the
Employment Agreement. Messrs. Ollet and Santi’s employment
agreement do not include the concept of good reason.
(2) Change of Control is generally defined (i) in the case of
Holman, as any Change of Control Event as defined in Treasury
Regulation Section 1.409A-3(i)(5); and (ii) in the case of Santi,
as (w) a sale of substantially all of the Company, (x) any “person”
(as such term is defined under the Exchange Act) becomes the
beneficial owners of over 50% of the Company’s voting power, (y) a
change in the majority of the composition of the Board or (z) a
transaction that results in over 50% of the Company’s voting power
ceasing to hold a majority of the voting power
post-transaction.
Risk Assessment Regarding Compensation Policies and Practices as
they Relate to Risk Management
Our compensation program for employees does not create incentives
for excessive risk taking by our employees or involve risks that
are reasonably likely to have a material adverse effect on us. Our
compensation has the following risk-limiting characteristics:
|
● |
Our base pay programs consist of competitive salary rates that
represent a reasonable portion of total compensation and provide a
reliable level of income on a regular basis, which decreases
incentive on the part of our executives to take unnecessary or
imprudent risks; and
|
|
● |
Cash bonus awards are not tied to formulas that could focus
executives on specific short-term outcomes.
|
Outstanding Awards at Fiscal Year End
Listed below is information with respect to unexercised options
that have not vested, and equity incentive plan awards for each
named executive officer outstanding as of December 31, 2021:
Outstanding Equity Awards at 2021 Fiscal Year-End
|
|
Number of Shares Issued Under Stock Options
|
|
|
Number of Shares Issued
Under Restricted Stock
|
|
|
Stock Options and Restricted Stock Exercise
Price ($) Per
Share of Stock
|
|
Expiration Date
|
|
Number of Shares
That
Have Not Vested (#)
|
|
|
Market Value of
Shares That Name Have
Not Vested ($)
|
|
Jeffrey Holman
|
|
|
-
|
|
|
|
9,075,000,000
|
|
|
|
0.0001
|
|
8/13/2028
|
|
|
9,075,000,000
|
|
|
|
907,500
|
|
Jeffrey Holman
|
|
|
39,000,000,000
|
|
|
|
-
|
|
|
|
0.0001
|
|
2/1/2027
|
|
|
-
|
|
|
|
-
|
|
Christopher Santi
|
|
|
-
|
|
|
|
6,600,000,000
|
|
|
|
0.0001
|
|
8/13/2028
|
|
|
6,600,000,000
|
|
|
|
660,000
|
|
Christopher Santi
|
|
|
17,000,000,000
|
|
|
|
-
|
|
|
|
0.0001
|
|
2/1/2027
|
|
|
-
|
|
|
|
-
|
|
John Ollet
|
|
|
-
|
|
|
|
2,475,000,000
|
|
|
|
0.0001
|
|
8/13/2028
|
|
|
2,475,000,000
|
|
|
|
247,500
|
|
John Ollet
|
|
|
1,000,000,000
|
|
|
|
-
|
|
|
|
0.0001
|
|
12/9/2026
|
|
|
-
|
|
|
|
-
|
|
John Ollet
|
|
|
4,000,000,000
|
|
|
|
-
|
|
|
|
0.0001
|
|
8/30/2027
|
|
|
-
|
|
|
|
-
|
|
Director Compensation
Non-employee directors are paid a monthly fee of $1,000 per month
and $1,000 for each meeting attended. Because we do not pay any
compensation to employee directors, Mr. Holman is omitted from the
following table. Non-employee members of our Board of Directors
were compensated for as follows:
Fiscal 2021 Director Compensation
Name
|
Fees Earned or Paid in Cash ($)
|
|
|
|
|
Dr. Anthony Panariello
|
|
$
|
26,000
|
|
Clifford J. Friedman
|
|
$
|
26,000
|
|
Equity Compensation Plan Information
The 2015 Equity Incentive Plan (the “Plan”) was approved by the
Company’s stockholders at the June 26, 2015 stockholders meeting.
On November 21, 2016, the Company’s Board of Directors increased
the number of shares of common stock available for issuance
pursuant to the Plan to 100,000,000,000. The Plan is a broad-based
plan in which all employees, consultants, officers, and directors
of the Company are eligible to participate. The purpose of the Plan
is to further the growth and development of the Company by
providing, through ownership of stock of the Company and other
equity-based awards, an incentive to its officers and other key
employees and consultants who are in a position to contribute
materially to the prosperity of the Company, to increase such
persons’ interests in the Company’s welfare, by encouraging them to
continue their services to the Company, and by enabling the Company
to attract individuals of outstanding ability to become employees,
consultants, officers and directors of the Company.
The
following chart reflects the number of awards granted under equity
compensation plans approved and not approved by stockholders and
the weighted average exercise price for such plans as of December
31, 2021.
Name of Plan
|
|
Number of securities to be issued upon exercise of outstanding
options, warrants and rights (a)
|
|
|
Weighted average exercise price of outstanding options, warrants
and rights (b)
|
|
|
Number of securities remaining available for future issuance under
equity compensation plans (excluding securities reflected in column
(a)) (c)
|
|
Equity compensation plans approved by security holders
|
|
|
|
|
|
|
|
|
|
2015 Equity Incentive Plan
|
|
|
89,712,508,480
|
|
|
|
0.0001
|
|
|
|
10,287,491,520
|
|
Total
|
|
|
89,712,508,480
|
|
|
|
-
|
|
|
|
10,287,491,520
|
|
Item
12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholders Matters.
The
following table sets forth the number of shares of our common stock
beneficially owned as of December 31, 2021,
by (i) those persons known by us to be owners of more than 5% of
our common stock, (ii) each director, (iii) our Named Executive
Officers and (iv) all of our executive officers and directors of as
a group. Unless otherwise specified in the notes to this table, the
address for each person is: c/o Healthier Choices Management Corp.,
3800 North 28th Way, Hollywood, Florida 33020.
Title of Class
|
Beneficial Owner
|
|
Amount and Nature of Beneficial Owner (1)
|
|
|
Percent of Class (1)
|
|
Directors and Executive Officers:
|
|
|
|
|
|
|
|
Common Stock
|
Jeffrey E. Holman (2)
|
|
|
43,537,500,000
|
|
|
|
11.50
|
%
|
Common Stock
|
Christopher Santi (3)
|
|
|
20,300,000,000
|
|
|
|
5.69
|
%
|
Common Stock
|
John Ollet (4)
|
|
|
6,237,500,000
|
|
|
|
1.81
|
%
|
Common Stock
|
Dr. Anthony Panariello (5)
|
|
|
1,206,250,000
|
|
|
|
0.35
|
%
|
Common Stock
|
Clifford J. Friedman (6)
|
|
|
1,500,000,000
|
|
|
|
0.44
|
%
|
All directors and officers as a group (5 persons) (7)
|
|
|
72,781,250,000
|
|
|
|
18.07
|
%
|
|
|
|
|
|
|
|
|
|
|
5% Stockholders:
|
|
|
|
|
|
|
|
|
|
None
|
|
|
|
-
|
|
|
|
0
|
%
|
Total:
|
|
|
|
72,781,250,000
|
|
|
|
18.07
|
%
|
(1) Beneficial
Ownership. Applicable percentages are based on
339,741,632,384 shares
of common stock outstanding as of March 31, 2022.
Beneficial ownership is determined under the rules of the SEC and
generally includes voting or investment power with respect to
securities. Shares of common stock subject to options, warrants,
convertible notes and preferred stock currently exercisable or
convertible or exercisable or convertible within 60 days are deemed
outstanding for computing the percentage of the person holding such
securities but are not deemed outstanding for computing the
percentage of any other person. The table includes shares of common
stock, options, warrants, and preferred stock exercisable or
convertible into common stock and vested or vesting within 60 days.
Unless otherwise indicated in the footnotes to this table, we
believe that each of the stockholders named in the table has sole
voting and investment power with respect to the shares of common
stock indicated as beneficially owned by them. The table does not
include: (i) restricted stock units that do not have the right to
vote until they vest and the shares are delivered or (ii) unvested
options that do not vest within 60 days of the date listed above in
this footnote.
(2) Holman.
Chairman and Chief Executive Officer. Includes 39,000,000,000
vested options and 4,537,500,000 shares of unvested restricted
Common Stock. This restricted stock vests 12.5% on the last day of
each calendar quarter commencing March 31, 2021.
(3) Santi.
President and Chief Operation Officer. Includes 17,000,000,000
vested options and 3,300,000,000 shares of unvested restricted
Common Stock. This restricted stock vests 12.5% on the last day of
each calendar quarter commencing March 31, 2021.
(4) Ollet.
Chief Financial Officer. Includes 5,000,000,000 vested options. He
also holds 1,237,500,000 shares of unvested restricted Common
Stock. This restricted stock vests 12.5% on the last day of each
calendar quarter commencing March 31, 2021.
(5) Panariello.
A director. Includes 1,000,000,000 vested options. He also holds
206,250,000 shares of unvested restricted Common Stock. This
restricted stock vests 12.5% on the last day of each calendar
quarter commencing March 31, 2021.
(6) Friedman.
A director. Includes 990,000,000 vested options and 510,000,000
shares of Common Stock.
(7) Directors
and Executive Officers. Includes executive officers who are not
Named Executive Officers under the SEC’s rules and
regulations.
Item 13. Certain Relationships and Related Transactions, and
Director Independence.
For the year ended December 31, 2021, the Company did not have any
related party transactions.
Policies and Procedures for Related Party Transactions
We have adopted a policy that our executive officers, directors,
nominees for election as a director, beneficial owners of more than
5% of any class of our common stock and any members of the
immediate family of any of the foregoing persons are not permitted
to enter into a related person transaction with us without the
prior consent of our audit committee. Our audit committee will
review and oversee all transactions with an executive officer,
director, nominee for election as a director, beneficial owner of
more than 5% of any class of our common stock or any member of the
immediate family of any of the foregoing persons and such person
would have a direct or indirect interest. In approving or rejecting
any such transactions, our audit committee is to consider the
material facts of the transaction, including, but not limited to,
whether the transaction is on terms no less favorable than terms
generally available to an unaffiliated third party under the same
or similar circumstances and the extent of the related person’s
interest in the transaction.
Item 14.
Principal Accounting Fees and Services.
Our Audit Committee pre-approves audit and permissible non-audit
services performed by its independent registered public accounting
firm, as well as the fees charged for such services. All of the
services related to audit fees and audit-related fees charged were
pre-approved by the Audit Committee. The following table shows the
fees for the years ended December 31, 2021 and 2020.
|
|
2021 ($)
|
|
|
2020 ($)
|
|
Audit Fees (1)
|
|
$
|
226,000
|
|
|
$
|
188,000
|
|
Total
|
|
$
|
226,000
|
|
|
$
|
188,000
|
|
(1) Audit
fees — these fees relate to the audit of our annual financial
statements and the review of our interim quarterly financial
statements and our registration statements.
PART IV
Item 15.
Exhibits, Financial Statement Schedules.
(a)
|
Documents filed as part of the report.
|
(1)
|
Financial Statements. See Index to Consolidated Financial
Statements, which appears on page F-1 hereof. The financial
statements listed in the accompanying Index to Consolidated
Financial Statements are filed herewith in response to this
Item.
|
(2)
|
Financial Statements Schedules. All schedules are omitted
because they are not applicable or because the required information
is contained in the consolidated financial statements or notes
included in this report.
|
(3)
|
Exhibits. The exhibits listed in the accompanying Exhibit Index are
filed or incorporated by reference as part of this report.
|
FINANCIAL STATEMENT INDEX
Report of Independent Registered Public Accounting Firm (PCAOB ID #
688)
|
|
|
|
Consolidated Financial Statements
|
|
|
|
Consolidated Balance Sheets as of December 31, 2021 and 2020
|
|
|
|
Consolidated Statements of Operations for the Years Ended
December 31, 2021 and
2020
|
|
|
|
Consolidated Statements of Changes in Stockholders’ Equity for the
Years Ended December 31,
2021 and 2020
|
|
|
|
Consolidated Statements of Cash Flows for the Years Ended
December 31, 2021 and
2020
|
|
|
|
Notes to Consolidated Financial Statements
|
|
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
Healthier Choices Management Corp.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of
Healthier Choices Management Corp. (the “Company”) as of December
31, 2021 and 2021, the related consolidated statements of
operations, changes in stockholders’ equity and cash flows for each
of the two years in the period ended December 31, 2021, and the
related notes (collectively
referred to as the “financial statements”). In our opinion,
the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2021 and
2020, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2021, in
conformity with accounting principles generally accepted in the
United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on the
Company's financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be
independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of
the Company's internal control over financial reporting.
Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audit[s]
also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that
our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period
audit of the financial statements that were communicated or
required to be communicated to the audit committee and that: (1)
relate to accounts or disclosures that are material to the
financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no
critical audit matters.
/s/ Marcum LLP
Marcum LLP
We have served as the Company’s auditor since 2017.
New York, NY
March 31, 2022
HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED BALANCE SHEETS
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
CURRENT ASSETS
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
26,496,404
|
|
|
$
|
925,475
|
|
Accounts receivable
|
|
|
28,481
|
|
|
|
23,675
|
|
Notes receivable
|
|
|
247,915
|
|
|
|
-
|
|
Inventories
|
|
|
1,521,199
|
|
|
|
1,749,246
|
|
Prepaid expenses and vendor deposits
|
|
|
456,397
|
|
|
|
286,065
|
|
Investment
|
|
|
23,143
|
|
|
|
22,731
|
|
TOTAL CURRENT ASSETS
|
|
|
28,773,539
|
|
|
|
3,007,192
|
|
|
|
|
|
|
|
|
|
|
Restricted Cash
|
|
|
-
|
|
|
|
2,000,000
|
|
Property and equipment, net of accumulated depreciation
|
|
|
176,988
|
|
|
|
230,719
|
|
Intangible assets, net of accumulated amortization
|
|
|
947,593
|
|
|
|
1,248,352
|
|
Goodwill
|
|
|
916,000
|
|
|
|
916,000
|
|
Notes receivable
|
|
|
-
|
|
|
|
304,511
|
|
Right of use asset – operating lease, net
|
|
|
3,543,930
|
|
|
|
4,078,621
|
|
Other assets
|
|
|
85,437
|
|
|
|
89,598
|
|
TOTAL ASSETS
|
|
$
|
34,443,487
|
|
|
$
|
11,874,993
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
1,642,848
|
|
|
$
|
1,085,663
|
|
Contract liabilities
|
|
|
23,178
|
|
|
|
21,262
|
|
Operating lease liability, current
|
|
|
437,328
|
|
|
|
474,686
|
|
Current portion of line of credit
|
|
|
418,036
|
|
|
|
2,000,000
|
|
Current portion of loan payment
|
|
|
2,604
|
|
|
|
2,072,484
|
|
TOTAL CURRENT LIABILITIES
|
|
|
2,523,994
|
|
|
|
5,654,095
|
|
|
|
|
|
|
|
|
|
|
Loan payable, net of current portion
|
|
|
815
|
|
|
|
849,009
|
|
Operating lease liability, net of current
|
|
|
2,685,021
|
|
|
|
3,114,521
|
|
TOTAL LIABILITIES
|
|
|
5,209,830
|
|
|
|
9,617,625
|
|
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Series C convertible preferred stock, $1,000 par value per share, 30,000 shares authorized; 0 and 16,277 shares issued and outstanding as
of December 31, 2021 and
2020, respectively; aggregate liquidation preference of
$16.3 million for
2020.
|
|
|
-
|
|
|
|
16,277,116
|
|
Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 and 0 shares issued and outstanding as
of December 31, 2021
and 2020, respectively; aggregate liquidation preference of
$0.8 million
|
|
|
800,000
|
|
|
|
-
|
|
Common Stock, $0.0001 par
value per share, 750,000,000,000 shares authorized;
339,741,632,384 and
143,840,848,017 shares
issued and outstanding as of December 31, 2021 and 2020,
respectively
|
|
|
33,974,163
|
|
|
|
14,384,084
|
|
Additional paid-in capital
|
|
|
30,855,824
|
|
|
|
3,955,039
|
|
Accumulated deficit
|
|
|
(36,396,330
|
)
|
|
|
(32,358,871
|
)
|
TOTAL STOCKHOLDERS’ EQUITY
|
|
|
29,233,657
|
|
|
|
2,257,368
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
$
|
34,443,487
|
|
|
$
|
11,874,993
|
|
See notes to consolidated financial statements
HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
For the Year Ended December 31,
|
|
|
|
2021
|
|
|
2020
|
|
SALES:
|
|
|
|
|
|
|
Vapor sales, net
|
|
$
|
2,084,813
|
|
|
$
|
2,458,945
|
|
Grocery sales, net
|
|
|
11,235,041
|
|
|
|
11,461,800
|
|
TOTAL SALES, NET
|
|
|
13,319,854
|
|
|
|
13,920,745
|
|
|
|
|
|
|
|
|
|
|
Cost of sales vapor
|
|
|
839,599
|
|
|
|
1,033,805
|
|
Cost of sales grocery
|
|
|
7,187,701
|
|
|
|
7,109,719
|
|
GROSS PROFIT
|
|
|
5,292,554
|
|
|
|
5,777,221
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
380,646
|
|
Selling, general and administrative
|
|
|
10,033,048
|
|
|
|
8,844,947
|
|
Total operating expenses
|
|
|
10,033,048
|
|
|
|
9,225,593
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS
|
|
|
(4,740,494
|
)
|
|
|
(3,448,372
|
)
|
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE):
|
|
|
|
|
|
|
|
|
Gain on debt settlements
|
|
|
767,930
|
|
|
|
-
|
|
Other expense, net
|
|
|
(26
|
)
|
|
|
(100
|
)
|
Interest expense, net
|
|
|
(65,281
|
)
|
|
|
(272,651
|
)
|
Gain (loss) on investment
|
|
|
412
|
|
|
|
(1,269
|
)
|
Total other income (expense), net
|
|
|
703,035
|
|
|
|
(274,020
|
)
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
$
|
(4,037,459
|
)
|
|
$
|
(3,722,392
|
)
|
|
|
|
|
|
|
|
|
|
NET LOSS PER SHARE BASIC AND DILUTED
|
|
$
|
0.00
|
|
|
$
|
0.00
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
|
|
|
|
|
|
|
|
BASIC AND DILUTED
|
|
|
307,912,959,368
|
|
|
|
90,351,540,618
|
|
See notes to consolidated financial statements
HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS’
EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
|
|
Convertible Preferred Stock
|
|
|
Common Stock
|
|
|
Additional Paid-In
|
|
|
Accumulated
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Total
|
|
Balance – January 1,
2020
|
|
|
20,150
|
|
|
$
|
20,150,116
|
|
|
|
67,698,494,244
|
|
|
$
|
6,769,849
|
|
|
$
|
7,618,245
|
|
|
$
|
(28,636,479
|
)
|
|
$
|
5,901,731
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock in connection with cashless exercise of
Series A warrants
|
|
|
-
|
|
|
|
-
|
|
|
|
37,412,353,772
|
|
|
|
3,741,235
|
|
|
|
(3,741,235
|
)
|
|
|
-
|
|
|
|
-
|
|
Cancellation of Series B Convertible Preferred Stock
|
|
|
(20,150
|
)
|
|
|
(20,150,116
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(20,150,116
|
)
|
Issuance of Series C Convertible Preferred Stock
|
|
|
20,150
|
|
|
|
20,150,116
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
20,150,116
|
|
Series C Preferred stock exercised
|
|
|
(3,873
|
)
|
|
|
(3,873,000
|
)
|
|
|
38,730,000,001
|
|
|
|
3,873,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
78,029
|
|
|
|
-
|
|
|
|
78,029
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,722,392
|
)
|
|
|
(3,722,392
|
)
|
Balance – December 31, 2020
|
|
|
16,277
|
|
|
|
16,277,116
|
|
|
|
143,840,848,017
|
|
|
$
|
14,384,084
|
|
|
$
|
3,955,039
|
|
|
$
|
(32,358,871
|
)
|
|
$
|
2,257,368
|
|
Series C Preferred stock exercised
|
|
|
(16,277
|
)
|
|
|
(16,277,116
|
)
|
|
|
162,771,153,001
|
|
|
|
16,277,116
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Stock options exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
2,275,000,000
|
|
|
|
227,500
|
|
|
|
-
|
|
|
|
-
|
|
|
|
227,500
|
|
Issuance of Series D Convertible Preferred stock in connection with
the Securities Purchase Agreement
|
|
|
5,000
|
|
|
|
5,000,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,000,000
|
|
Series D Convertible Preferred Stock exercised
|
|
|
(4,200
|
)
|
|
|
(4,200,000
|
)
|
|
|
6,562,500,000
|
|
|
|
656,250
|
|
|
|
3,543,750
|
|
|
|
-
|
|
|
|
-
|
|
Issuance of common stock
|
|
|
-
|
|
|
|
-
|
|
|
|
1,182,831,056
|
|
|
|
118,283
|
|
|
|
1,289,273
|
|
|
|
-
|
|
|
|
1,407,556
|
|
Issuance of common stock in connection with the Rights Offering,
net of offering expenses
|
|
|
-
|
|
|
|
-
|
|
|
|
27,046,800,310
|
|
|
|
2,704,680
|
|
|
|
21,639,637
|
|
|
|
-
|
|
|
|
24,344,317
|
|
Issuance of awarded stock for officers
|
|
|
-
|
|
|
|
-
|
|
|
|
2,200,000,000
|
|
|
|
220,000
|
|
|
|
(220,000
|
)
|
|
|
-
|
|
|
|
-
|
|
Issuance of awarded stock for board member
|
|
|
-
|
|
|
|
-
|
|
|
|
50,000,000
|
|
|
|
5,000
|
|
|
|
(5,000
|
)
|
|
|
-
|
|
|
|
-
|
|
Cancellation of awarded stock for officers
|
|
|
-
|
|
|
|
-
|
|
|
|
(6,050,000,000
|
)
|
|
|
(605,000
|
)
|
|
|
605,000
|
|
|
|
-
|
|
|
|
-
|
|
Cancellation of awarded stock for board member
|
|
|
-
|
|
|
|
-
|
|
|
|
(137,500,000
|
)
|
|
|
(13,750
|
)
|
|
|
13,750
|
|
|
|
-
|
|
|
|
-
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
34,375
|
|
|
|
-
|
|
|
|
34,375
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,037,459
|
)
|
|
|
(4,037,459
|
)
|
Balance – December 31, 2021
|
|
|
800
|
|
|
$
|
800,000
|
|
|
|
339,741,632,384
|
|
|
$
|
33,974,163
|
|
|
$
|
30,855,824
|
|
|
$
|
(36,396,330
|
)
|
|
$
|
29,233,657
|
|
See notes to consolidated financial statements
HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF
CASH FLOWS
|
|
For the year ended December 31,
|
|
|
|
2021
|
|
|
2020
|
|
OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(4,037,459
|
)
|
|
$
|
(3,722,392
|
)
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
497,408
|
|
|
|
550,098
|
|
Net gain on debt settlements
|
|
|
(767,930
|
)
|
|
|
-
|
|
Amortization of right-of-use asset
|
|
|
534,691
|
|
|
|
584,398
|
|
Gain (loss) on investment
|
|
|
(412
|
)
|
|
|
1,269
|
|
Write-down of obsolete and slow-moving inventory
|
|
|
707,710
|
|
|
|
340,905
|
|
Stock-based compensation expense
|
|
|
34,375
|
|
|
|
78,029
|
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
380,646
|
|
Accrued interest on loan payable
|
|
|
60,809
|
|
|
|
7,117
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(4,806
|
)
|
|
|
41,726
|
|
Inventories
|
|
|
(478,663
|
)
|
|
|
(333,139
|
)
|
Prepaid expenses and vendor deposits
|
|
|
(170,332
|
)
|
|
|
(16,233
|
)
|
Contract assets
|
|
|
-
|
|
|
|
-
|
|
Other assets
|
|
|
4,161
|
|
|
|
57,269
|
|
Accounts payable and accrued liabilities
|
|
|
557,185
|
|
|
|
265,552
|
|
Contract liabilities
|
|
|
1,916
|
|
|
|
(5,561
|
)
|
Lease liability
|
|
|
(466,858
|
)
|
|
|
(511,481
|
)
|
NET CASH USED IN OPERATING ACTIVITIES
|
|
|
(3,528,205
|
)
|
|
|
(2,281,797
|
)
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Payment for acquisition
|
|
|
(75,000
|
)
|
|
|
-
|
|
Collection of note receivable
|
|
|
56,596
|
|
|
|
38,876
|
|
Purchases of patent
|
|
|
(12,500
|
)
|
|
|
(89,415
|
)
|
Purchases of property and equipment
|
|
|
(56,418
|
)
|
|
|
(24,663
|
)
|
NET CASH USED IN INVESTING ACTIVITIES
|
|
|
(87,322
|
)
|
|
|
(75,202
|
)
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Proceeds from line of credit
|
|
|
418,036
|
|
|
|
-
|
|
Principal payment on the line of credit
|
|
|
(2,000,000
|
)
|
|
|
-
|
|
Principal payments on loan payable
|
|
|
(803,397
|
)
|
|
|
(1,659,456
|
)
|
Proceeds from paycheck protection program
|
|
|
-
|
|
|
|
876,515
|
|
Proceeds from loan and security agreement
|
|
|
-
|
|
|
|
2,540,000
|
|
Proceeds from issuance of preferred stock
|
|
|
5,000,000
|
|
|
|
-
|
|
Proceeds from rights offering, net of offering costs
|
|
|
24,344,317
|
|
|
|
-
|
|
Proceeds from exercise of stock options
|
|
|
227,500
|
|
|
|
-
|
|
NET CASH PROVIDED BY FINANCING ACTIVITIES
|
|
|
27,186,456
|
|
|
|
1,757,059
|
|
|
|
|
|
|
|
|
|
|
INCREASE (DECREASE) IN CASH
|
|
|
23,570,929
|
|
|
|
(599,940
|
)
|
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF
YEAR
|
|
|
2,925,475
|
|
|
|
3,525,415
|
|
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF YEAR
|
|
$
|
26,496,404
|
|
|
$
|
2,925,475
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
115,584
|
|
|
$
|
314,925
|
|
NON-CASH INVESTING AND FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Issuance of common stock in connection with the exchange
agreement
|
|
$
|
1,407,556
|
|
|
$
|
-
|
|
See notes to consolidated financial statements
HEALTHIER CHOICES MANAGEMENT CORP.
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
Note 1. ORGANIZATION, BASIS OF PRESENTATION, AND RECENT
DEVELOPMENTS
Organization
Healthier Choices Management Corp. (the “Company”) is a holding
company focused on providing consumers with healthier daily choices
with respect to nutrition and other lifestyle alternatives. The
Company currently operates six retail vape stores in the Southeast
region of the United States, through which it offers e-liquids,
vaporizers and related products. The Company also operates Ada’s
Natural Market, a natural and organic grocery store, through its
wholly owned subsidiary Healthy Choice Markets, Inc. Ada’s Natural
Market and Paradise Health and Nutrition offers fresh produce, bulk
foods, vitamins and supplements, packaged groceries, meat and
seafood, deli, baked goods, dairy products, frozen foods, health
& beauty products and natural household items. The Company also
sells vitamins and supplements on the Amazon.com marketplace
through its wholly owned subsidiary Healthy U Wholesale, Inc. The
Company also operates HCMC Intellectual Property Holdings, LLC, a
wholly owned subsidiary formed to hold, market and expand on its
current intellectual property assets. The Company markets the
Q-Cup™ technology under the vape segment; this patented technology
is based on a small, quartz cup called the Q-Cup™, which a customer
partially fills with either cannabis or CBD concentrate
(approximately 50mg) purchased from a third party. The Q-Cup™ is
then inserted into the Q-Cup™ Tank or Globe, that heats the cup
from the outside without coming in direct contact with the solid
concentrate. This Q-Cup™ technology provides significantly more
efficiency and an “on the go” solution for consumers who prefer to
vape concentrates either medicinally or recreationally. The Company
acquired Mother Earth’s Storehouse on February 2022, which operates
a two store organic and health food and vitamin chain in New York’s
Hudson Valley, a business that has been operating for over 40
years.
COVID-19 Management Update
The global outbreak of COVID-19 was declared a pandemic by the
World Health Organization and a national emergency by the U.S.
government in March 2020 and has negatively impacted the U.S. and
global economies, disrupted global supply chains and, mandated
closures and stay-at-home orders and created significant
disruptions of the global financial markets. The Company adjusted
certain aspects of the operations to protect their employees and
customers while still meeting customers’ needs. While to date the
Company has not been required to close any of its stores, the
Company is currently operating under regular hours and we are
expecting COVID-19 to have a long-term beneficial impact to the
future financial results of the grocery segment. The Company
continues to monitor the impact of the COVID-19 outbreak
closely. The extent to which the COVID-19 outbreak will
impact our operations is manageable, and there is no imminent risk
on business continuity and future operations.
Sourcing and Vendors
We source from multiple suppliers. These suppliers range from small
independent businesses to multinational conglomerates. For the
fiscal years ended December 31, 2021 and 2020, approximately 25%
and 27% of our total purchases were from one vendor.
Basis of Presentation and Principles of Consolidation
The Company’s consolidated financial statements are prepared in
accordance with GAAP. The consolidated financial statements include
the accounts of all subsidiaries in which the Company holds a
controlling financial interest as of the financial statement
date.
The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries, Healthy Choice Markets,
Inc., Healthy Choice Markets 2, LLC (“Paradise Health and
Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s
Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC
Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC,
The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store,
Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere
U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”),
IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and
Vaporin Florida, Inc. All intercompany accounts and transactions
have been eliminated in consolidation.
Note 2. LIQUIDITY
The accompanying condensed consolidated financial statements have
been prepared in conformity with accounting principles generally
accepted in the United States of America (“GAAP”), which
contemplate continuation of the Company as a going concern and
realization of assets and satisfaction of liabilities in the normal
course of business and do not include any adjustments that might
result from the outcome of any uncertainties related to our going
concern assessment. The carrying amounts of assets and liabilities
presented in the financial statements do not necessarily purport to
represent realizable or settlement values.
The Company incurred a loss from operations of approximately $4.7
million for the year ended December 31, 2021. As of December 31,
2021, cash and cash equivalents totaled approximately $26.5
million. Management anticipates that its current cash, cash
equivalent and cash generated from operations will be sufficient to
meet the projected operating expenses for the foreseeable future
through at least the next twelve months from the issuance of these
consolidated financial statements.
Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Segment Reporting
Operating segments are identified as components of an enterprise
about which separate discrete financial information is available
for evaluation by the operating decision makers, or decision-making
group, in making decisions on how to allocate resources and assess
performance. The Company’s decision-making group are the senior
executive management team. The Company and the decision-making
group view the Company’s operations and manage its business as two
operating segments. All long-lived assets of the Company reside in
the U.S.
Use of Estimates in the Preparation of the Financial
Statements
The preparation of consolidated financial statements in conformity
with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of net
revenue and expenses during the reporting periods. Actual results
could differ from those estimates. These estimates and assumptions
include allowances, reserves and write-downs of inventory, valuing
equity securities and hybrid instruments, share-based payment
arrangements, deferred taxes and related valuation allowances, and
the valuation of the assets and liabilities acquired in business
combinations. Certain of management’s estimates could be affected
by external conditions, including those unique to our industry, and
general economic conditions. It is possible that these external
factors could have an effect on our estimates that could cause
actual results to differ from our estimates. The Company
re-evaluates all of its accounting estimates at least quarterly
based on these conditions and records adjustments when
necessary.
Revenue Recognition
Revenues from product sales and services rendered, net of
promotional discounts, manufacturer coupons and rebates, return
allowances, and sales and consumption taxes, are recorded when
products are delivered, title passes to customers and collection is
likely to occur. Title passes to customers at the point of sale for
retail and upon delivery of products for wholesale. Return
allowances, which reduce revenue, are estimated using historical
experience.
The Company recognizes revenue in accordance with the following
five-step model:
|
● |
identify arrangements with customers;
|
|
● |
identify performance obligations;
|
|
● |
determine transaction price;
|
|
● |
allocate transaction price to the separate performance obligations
in the arrangement, if more than one exists; and
|
|
● |
recognize revenue as performance obligations are satisfied.
|
Shipping and Handling
Shipping charges billed to customers are included in net sales and
the related shipping and handling costs are included in cost of
sales. For the years ended December 31, 2021 and 2020, shipping and
handling costs of approximately $68,000 and $48,000, were included
in cost of sales, respectively.
Cash and Cash Equivalents
The Company considers all highly liquid instruments with an
original maturity of three months or less, when purchased, to be
cash and cash equivalents. The majority of the Company’s cash and
cash equivalents are concentrated in one large financial
institution, which is in excess of Federal Deposit Insurance
Corporation (FDIC) coverage. At December 31, 2021, cash in excess
of FDIC limits of $250,000 per financial institution were
approximately $26.0 million. The Company continually monitors its
positions with, and the credit quality of, the financial
institutions with which it invests, as deposits are held in excess
of federally insured limits. The Company’s cash equivalent at
December 31, 2021 was a money market account. The Company has not
experienced any losses in such accounts.
Accounts Receivable, Contract Assets and Contract Liabilities
Accounts receivables are claims to consideration which are
unconditional; meaning no performance obligations remain for the
Company and only the passage of time is necessary before
collection. Contract assets are distinguished from accounts
receivable as performance obligations remain before claims to
consideration become unconditional. By nature of the Company’s
operations, contract assets are typically not recognized. Contract
liabilities are recorded when customers transfer consideration in
advance of delivery of products or services, which the Company
records for gift cards and loyalty reward programs. When one party
to an arrangement performs before the other(s), the Company records
an account receivable, contract asset or contract liability.
The majority of arrangements with customers contain one performance
obligation: to provide a distinct set of products or services. Most
performance obligations are satisfied simultaneously as the Company
exchanges products or services for customer payment. Exceptions
include gift cards and loyalty rewards, for which the Company has a
performance obligation to deliver products or services at a future
date. As gift cards are purchased and loyalty points earned,
contract liabilities are recorded until the performance obligations
are satisfied through delivery of products or services or breakage
based on gift card and loyalty reward program term limits.
The Company’s breakage policy is twenty-four
months for gift cards, twelve months for Grocery loyalty
rewards, and six months for Vapor loyalty rewards. Loyalty rewards
are earned at five
percent on qualifying purchases and the reward functions as an
allocation of transaction price from the period earned by the
customer to the period the performance obligation is satisfied by
the Company. As such, all contract liabilities are expected to be
recognized within a twenty-four
month period.
Concentration of accounts receivable consist of the
following:
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Customer A
|
|
|
30
|
%
|
|
|
0
|
%
|
Customer B
|
|
|
12
|
%
|
|
|
0
|
%
|
Customer C
|
|
|
0
|
%
|
|
|
34
|
%
|
Due from Merchant Credit Card Processor
Due from merchant credit card processor represents monies held by
the Company’s credit card processors. The funds are being held by
the merchant credit card processors pending satisfaction of their
hold requirements and expiration of charge backs/refunds from
customers.
Inventories
Inventories are stated at average cost. If the cost of the
inventories exceeds their net realizable value, adjustments are
recorded to write down excess inventory to their net realizable
value. The Company’s inventories consist primarily of merchandise
available for resale, such as vaporizers, electronic cigarettes,
e-liquids, fresh produce, perishable grocery items and
non-perishable consumable goods.
Property and Equipment
Property and equipment are stated at cost less accumulated
depreciation. Depreciation is calculated using the straight-line
method over the expected useful life of the respective asset, after
the asset is placed in service. Revenue earning property and
equipment includes signage, furniture and fixtures, computer
hardware, appliance, cooler, displays with useful lives range from
two
to seven years. Leasehold improvements are amortized over life of
lease.
Identifiable Intangible Assets and Goodwill
Identifiable intangible assets are recorded at cost, or when
acquired as part of a business acquisition, at estimated fair
value. Certain identifiable intangible assets are amortized over 4
and 10 years. Similar to tangible personal property and equipment,
the Company periodically evaluates identifiable intangible assets
for impairment whenever events or changes in circumstances indicate
that the carrying amount may not be recoverable. Indefinite-lived
intangible assets, such as goodwill are not amortized.
Impairment of Long-Lived Assets
The Company reviews all long-lived assets such as property and
equipment and amortized intangible assets for impairment whenever
events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of
an asset to the estimated future cash flows expected to be
generated by the asset or asset group. Impairment is measured by
the amount by which the carrying value of the asset(s) exceeds
their fair value. There were no triggering events that would
indicate impairment of long-lived assets at December 31, 2021. For
the year ended December 31, 2020, the Company determined the
estimated undiscounted cash flows related to the sales of the
VitaminStore.com were less than the carrying value of the
intangible assets and recorded an impairment charge of $0.3
million.
Goodwill
The Company assesses the carrying amounts of goodwill for
recoverability on at least an annual basis or when events or
changes in circumstances indicate evidence of potential impairment
exists, using a fair value based test. Application of the goodwill
impairment test requires significant judgments including estimation
of future cash flows, which is dependent on internal forecasts,
estimation of the long-term rate of growth for the businesses, and
the useful life over which cash flows will occur. Changes in these
estimates and assumptions could materially affect the determination
of fair value and/or conclusions on goodwill impairment for the
Company. Our annual impairment test is conducted on September 30 of
each year or more often if deemed necessary. As part of
management's qualitative analysis at December 31, 2021 management
determines whether any triggering events have occurred since the
annual test date of September 30, 2021, which would indicate an
impairment. Management determined no triggering events had occurred
through December 31, 2021. The Company recorded an impairment
charge of $40,000 for the year ended December 31, 2020.
Advertising
The Company expenses advertising costs as incurred. For the years
ended December 31, 2021 and 2020, the company incurred advertising
expenses of $43,000 and $92,000, respectively.
Income Taxes
The Company uses the asset and liability method of accounting for
income taxes in accordance with ASC 740, “Income Taxes” (“ASC
740”). Under this method, income tax expense is recognized as the
amount of: (i) taxes payable or refundable for the current year and
(ii) future tax consequences attributable to differences between
financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply
to taxable income in the years which those temporary differences
are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in
the results of operations in the period that includes the enactment
date. A valuation allowance is provided to reduce the deferred tax
assets reported if based on the weight of available evidence it is
more likely than not that some portion or all of the deferred tax
assets will not be realized.
ASC
740 prescribes a recognition threshold and a measurement attribute
for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those
benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. The
Company recognizes accrued interest and penalties related to
unrecognized tax benefits as income tax expense. There were no
unrecognized tax benefits and no amounts accrued for interest and
penalties as of December 31, 2021 or December 31, 2020. The Company
is currently not aware of any issues under review that could result
in significant payments, accruals or material deviation from its
position.
Stock-Based Compensation
The Company accounts for stock-based compensation for employees and
directors under ASC Topic No. 718, “Compensation-Stock
Compensation” (“ASC 718”). These standards define a fair value
based method of accounting for stock-based compensation. In
accordance with ASC 718, the cost of stock-based compensation is
measured at the grant date based on the value of the award and is
recognized over the vesting period. The value of the stock-based
award is determined using an appropriate valuation model, whereby
compensation cost is the fair value of the award as determined by
the valuation model at the grant date. The resulting amount is
charged to expense on the straight-line basis over the period in
which the Company expects to receive the benefit, which is
generally the vesting period. The Company recognize forfeitures as
they are incur. Stock-based compensation for non-employees is
measured at the grant date, is re-measured at subsequent vesting
dates and reporting dates, and is amortized over the service
period.
Fair Value Measurements
The fair value framework under FASB’s guidance requires the
categorization of assets and liabilities into three levels based
upon the assumptions used to measure the assets or liabilities.
Level 1 provides the most reliable measure of fair value, whereas
Level 3, if applicable, would generally require significant
management judgment. The three levels for categorizing assets and
liabilities under the fair value measurement requirements are as
follows:
|
● |
Level 1: Fair value measurement of the asset or liability using
observable inputs such as quoted prices in active markets for
identical assets or liabilities;
|
|
● |
Level 2: Fair value measurement of the asset or liability using
inputs other than quoted prices that are observable for the
applicable asset or liability, either directly or indirectly, such
as quoted prices for similar (as opposed to identical) assets or
liabilities in active markets and quoted prices for identical or
similar assets or liabilities in markets that are not active;
and
|
|
● |
Level 3: Fair value measurement of the asset or liability using
unobservable inputs that reflect the Company’s own assumptions
regarding the applicable asset or liability.
|
Nonfinancial assets such as goodwill, other intangible assets, and
long-lived assets held and used are measured at fair value when
there is an indicator of impairment and recorded at fair value when
impairment is recognized or for a business combination.
Sequencing Policy
Under ASC 815-40-35, the Company has adopted a sequencing policy,
whereby, in the event that reclassification of contracts from
equity to assets or liabilities is necessary pursuant to ASC 815
due to the Company’s inability to demonstrate it has sufficient
authorized shares, shares will be allocated on the basis of the
earliest issuance date of potentially dilutive instruments, with
the earliest grants receiving the first allocation of shares.
Note 4. DISAGGREGATION OF REVENUES
The Company reports the following segments in accordance with
management guidance: Vapor and Grocery. When the Company prepares
its internal management reporting to evaluate business performance,
we disaggregate revenue into the following categories that depict
how the nature, amount, timing and uncertainty of revenue and cash
flows are affected by economic factors.
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Vapor sales, net
|
|
$
|
2,084,813
|
|
|
$
|
2,458,945
|
|
Grocery sales, net
|
|
|
11,235,041
|
|
|
|
11,461,800
|
|
Total revenue
|
|
$
|
13,319,854
|
|
|
$
|
13,920,745
|
|
|
|
|
|
|
|
|
|
|
Retail Vapor
|
|
$
|
2,084,744
|
|
|
$
|
2,458,945
|
|
Retail Grocery
|
|
|
9,923,137
|
|
|
|
10,047,437
|
|
Food service/restaurant
|
|
|
1,202,122
|
|
|
|
1,088,162
|
|
Online/e-Commerce
|
|
|
93,600
|
|
|
|
307,487
|
|
Wholesale Grocery
|
|
|
16,182
|
|
|
|
18,714
|
|
Wholesale Vapor
|
|
|
69
|
|
|
|
-
|
|
Total revenue
|
|
$
|
13,319,854
|
|
|
$
|
13,920,745
|
|
Note 5. INVESTMENT
In 2018, the Company invested $150,000 in 85,714 common stock
shares at MJ Holdings, Inc. (“MJNE”), a publicly traded company.
The investment was made based on the assumption of an increase in
MJNE stock due to the sales agreement with the Company. The Company
recorded the investment in MJNE at fair value with changes in the
fair value reported through the income statement as the stock is
traded on the OTC market. Investment is classed with Level 1 of the
valuation hierarchy. Fair value for the investment is based on
quoted prices in active markets.
The following table summarizes the investment measured at fair
value on a recurring basis as of December 31, 2021:
Description
|
Fair Value Measurements Using Quoted Prices in Active Market (Level
1)
|
|
Mark to Market
|
|
December 31, 2021
|
|
Investment
|
|
$
|
22,731
|
|
|
$
|
412
|
|
|
$
|
23,143
|
|
The following table summarizes the investment measured at fair
value on a recurring basis as of December 31, 2020:
Description
|
Fair Value Measurements Using Quoted Prices in Active Market (Level
1)
|
|
Mark to Market
|
|
December 31, 2021
|
|
Investment
|
|
$
|
24,000
|
|
|
$
|
(1,269
|
)
|
|
$
|
22,731
|
|
Note 6. INVENTORIES
Inventories are stated at average cost. If the cost of the
inventories exceeds their market value, adjustments are recorded to
write down excess inventory to its net realizable value. Throughout
the year, the Company did not have independent third party counts
of its inventory due to the Coronavirus (COVID-19) pandemic and
recorded the write down of inventories amounting to $0.7 million
and $0.3 million, approximately, in 2021 and 2020, respectively.
The Company’s inventories consist primarily of merchandise
available for resale.
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Vapor Business
|
|
$
|
188,793
|
|
|
$
|
304,614
|
|
Grocery Business
|
|
|
1,332,406
|
|
|
|
1,444,632
|
|
Total
|
|
$
|
1,521,199
|
|
|
$
|
1,749,246
|
|
Note 7. NOTES RECEIVABLE AND OTHER INCOME
On September 6, 2018, the Company entered into a secured, 36-month
promissory note with VPR Brands L.P. for $582,260. The Note bears
an interest rate of 7%, which payments thereunder are $4,141
weekly. The Company records all proceeds related to the interest of
the Note as interest income as proceeds are received.
On August 31, 2021, the Company amended and restated the Secured
Promissory Note (the "Note") with VPRB Brands L.P. for the
outstanding balance in the note of $268,126. The Note bears an
interest rate of 7%, which payments thereunder are
$1,500 weekly, with such payments commencing as of September
03, 2021. The Note has a balloon payment of $213,028 for all
remaining accrued interest and principal balance due in the final
week of the 1-year extension of the Note.
A summary of the Note as of December 31, 2021 and 2020 is presented
below:
|
December 31,
|
|
Description
|
2021
|
|
2020
|
|
Promissory Note
|
|
$
|
247,915
|
|
|
$
|
304,511
|
|
For the years ended December 31, 2021 and 2020, the Company had
notes receivable collections of approximately $57,000 and $39,000,
respectively. These collections are recorded to other income in the
Consolidated Statement of Operations.
Note 8. PROPERTY & EQUIPMENT
Property and equipment consists of the following
|
|
Year Ended December 31,
|
|
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
Displays
|
|
$
|
305,558
|
|
|
$
|
305,558
|
|
Furniture and fixtures
|
|
|
246,496
|
|
|
|
246,496
|
|
Leasehold improvements
|
|
|
136,504
|
|
|
|
128,004
|
|
Computer hardware & equipment
|
|
|
151,924
|
|
|
|
143,082
|
|
Other
|
|
|
315,788
|
|
|
|
276,711
|
|
|
|
|
1,156,270
|
|
|
|
1,099,851
|
|
Less: accumulated depreciation and amortization
|
|
|
(979,282
|
)
|
|
|
(869,132
|
)
|
Total property and equipment
|
|
$
|
176,988
|
|
|
$
|
230,719
|
|
The Company incurred approximately $0.1 million and $0.1 million of
depreciation expense for the years ended December 31, 2021 and
2020, respectively.
Note 9. GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for the years ended
December 31, 2021 and 2020 are as follows:
|
|
December 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Beginning balance
|
|
$
|
916,000
|
|
|
$
|
956,000
|
|
Impairment of goodwill-retail business
|
|
|
-
|
|
|
|
(40,000
|
)
|
Ending balance
|
|
$
|
916,000
|
|
|
$
|
916,000
|
|
Intangible assets, net are as follows:
December 31, 2021
|
Useful Lives (Years)
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
Net Carrying Amount
|
|
Customer relationships
|
4-5 years
|
|
$
|
883,000
|
|
|
$
|
(685,823
|
)
|
|
$
|
197,177
|
|
Trade names
|
8-10 years
|
|
|
923,000
|
|
|
|
(536,661
|
)
|
|
|
386,339
|
|
Patents
|
10 years
|
|
|
372,165
|
|
|
|
(122,233
|
)
|
|
|
249,932
|
|
Non-compete
|
4 years
|
|
|
238,000
|
|
|
|
(133,646
|
)
|
|
|
104,354
|
|
Website
|
4 years
|
|
|
10,000
|
|
|
|
(209
|
)
|
|
|
9,791
|
|
Intangible assets, net
|
|
|
$
|
2,426,165
|
|
|
$
|
(1,478,572
|
)
|
|
$
|
947,593
|
|
December 31, 2020
|
Useful Lives (Years)
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
Net Carrying Amount
|
|
Customer relationships
|
4-10 years
|
|
$
|
883,000
|
|
|
$
|
(475,073
|
)
|
|
$
|
407,927
|
|
Trade names
|
8-10 years
|
|
|
923,000
|
|
|
|
(441,786
|
)
|
|
|
481,214
|
|
Patents
|
10 years
|
|
|
359,665
|
|
|
|
(85,641
|
)
|
|
|
274,024
|
|
Non-compete
|
4 years
|
|
|
174,000
|
|
|
|
(88,813
|
)
|
|
|
85,187
|
|
Intangible assets, net
|
|
|
$
|
2,339,665
|
|
|
$
|
(1,091,313
|
)
|
|
$
|
1,248,352
|
|
Amortization expense was approximately $0.4 million for the years
ended December 31, 2021 and 2020.
Acquisition of EIR Hydration
On
November 30, 2021,
the Company, through its wholly owned subsidiary, Healthy Choice
Wellness Center, LLP, acquired EIR Hydration, an IV therapy center
located in Roslyn Heights, NY. The cost of the transaction was
$75,000 and
it was treated as an asset purchase.
The weighted-average remaining amortization period of the Company’s
amortizable intangible assets is approximately 6 years as of
December 31, 2021. The estimated future amortization of the
intangible assets is as follows:
For the years ending December 31,
|
|
|
|
2022
|
|
$
|
389,456
|
|
2023
|
|
|
150,591
|
|
2024
|
|
|
150,591
|
|
2025
|
|
|
143,549
|
|
2026
|
|
|
48,655
|
|
Thereafter
|
|
|
64,751
|
|
Total
|
|
$
|
947,593
|
|
Note 10. CONTRACT LIABILITIES
The Company’s contract liabilities consist of customer deposits,
gift cards and loyalty rewards, for which the Company has a
performance obligation to deliver products when customers redeem
balances or terms expire through breakage. The Company’s breakage
policy is twenty-four
months for gift cards, twelve months for Grocery loyalty
rewards, and six months for Vapor loyalty rewards. As such, all
contract liabilities are expected to be recognized within a
twenty-four
month period.
A summary of the contract liabilities activity for the years ended
December 31, 2021 and 2020 is presented below:
|
|
Year ended December 31,
|
|
|
|
2021
|
|
|
2020
|
|
Beginning balance as of January1,
|
|
$
|
21,262
|
|
|
$
|
26,823
|
|
Issued
|
|
|
39,469
|
|
|
|
53,929
|
|
Redeemed
|
|
|
(37,463
|
)
|
|
|
(58,263
|
)
|
Breakage recognized
|
|
|
(90
|
)
|
|
|
(1,227
|
)
|
Ending balance as of December 31,
|
|
$
|
23,178
|
|
|
$
|
21,262
|
|
Note 11. LINE OF CREDIT AND DEBT
The following table provides a breakdown of the Company's debt as
of December 31, 2021 and 2020 is presented below:
|
December 31,
|
|
2021
|
|
2020
|
Line of Credit
|
$
|
418,036
|
|
$
|
2,000,000
|
Term Loan Credit Agreement
|
|
-
|
|
|
800,924
|
Paycheck Protection Program
|
|
-
|
|
|
882,264
|
Loan and Security Agreement ("PPE Loan")
|
|
-
|
|
|
1,232,414
|
Other debt
|
|
3,419
|
|
|
5,891
|
Total Line of Credit and Debt
|
$
|
421,455
|
|
$
|
4,921,493
|
On
November 3, 2021,
the Company entered into an agreement for a new revolving line of
credit of $2.0 million
and a blocked/restricted deposit account (“blocked account”) with
Professional Bank in Coral Gables, Florida. The agreement included
a variable interest rate that it is based on a rate
of 1.0% over
what is earned on the collateral account. Based on the
agreement with the bank, each draw request from the credit line
will be 100% cash
secured with moneys held from the blocked account.
Term Loan Credit Agreement
On December 31, 2018, the Company entered into a Term Loan Credit
Agreement (the “Credit Agreement”) with Professional Bank, a
Florida banking corporation (the “Bank”), pursuant to which the
Company issued a Term Note (the “Term Note”) in the principal
amount of $1,400,000 in favor of the Bank. The Term Note bears
interest at a rate equal to 1.5 percentage points in excess of that
rate shown in the Wall Street Journal as the prime rate, adjusted
annually (which was 5.50% as of December 31, 2020 and 2021). The
proceeds of the Term Note were used for acquisitions and for
general working capital requirements.
On December 21, 2021, the Company paid in full the outstanding
balance of $410,000 from the Term Loan.
Paycheck Protection Program
On May 15, 2020, the Company was granted a loan (the “Loan”) from
Customers Bank, in the aggregate amount of $876,515, pursuant to
the Paycheck Protection Program (the “PPP”) under Division A, Title
I of the CARES Act, which was enacted March 27, 2020.
The Loan, which was in the form of a Note dated May 6, 2020 issued
by the Company, matures on May 6, 2022 and bears interest at a rate
of 1% per annum, payable monthly commencing on November 6, 2020.
Note may be prepaid by the Borrower at any time prior to maturity
with no prepayment penalties. Funds from the Loan may only be used
for payroll costs, costs used to continue group health care
benefits, mortgage payments, rent, utilities, and interest on other
debt obligations incurred after May 6, 2020. The Company intends to
use the entire Loan amount for these qualifying expenses. Under the
terms of the PPP, certain amounts of the Loan may be forgiven if
they are used for qualifying expenses as described in the CARES
Act. On December 9, 2020, the Company submitted the forgiveness
application for the PPP Loan to the Small Business Bureau.
On May 3, 2021, the Company received a letter from Customers Bank
to inform the Company that the PPP Loan was paid and fully forgiven
by the Small Business Administration (SBA). The
forgiveness of $885,227 was reported in gain on debt settlements on
the consolidated statements of operations.
Note 12. COMMITMENTS AND CONTINGENCIES
Employment Agreements
On
August 13, 2018, the Company amended and restated its existing
employment agreement with Jeffrey Holman, the Company’s Chief
Executive Officer (the “Holman
Employment Agreement”).
The Holman Employment Agreement is for an additional three
year term
and provides for an annual base salary of $450 and
a target bonus for 2020 only in an amount ranging from 20%
to
200% of
his base salaries subject to the Company meeting certain earnings
before interest, taxes depreciation and amortization performance
milestones. Mr. Holman is entitled to receive severance payments,
including two years of
his then base salary and other benefits in the event of a change of
control, termination by the Company without cause, termination for
good reason by the executive or non-renewal by the Company. Mr.
Holman was also granted 11 billion
shares of restricted common stock pursuant to the Holman Employment
Agreement Amendment on the condition that 11 billion
of his options to purchase Company common stock are forfeited. This
restricted stock will vest one year following
the date of issuance provided that the grantee remains an employee
of the Company through each applicable vesting date. On August 12,
2019, the Company agreed to extend the expiration date of the
vesting period for the restricted stock by six months
to
February 13, 2020. On August 12, 2020, the Company agreed to extend
for a second time the expiration date of the vesting period for the
restricted stock by six months to
February 13, 2021. The Term shall be automatically renewed
for successive one-year terms unless notice of non-renewal is given
by either party at least 30 days before the end of the Term.
The
above description of the terms of the Holman Employment Agreement
is not complete and is qualified by reference to the complete
document.
On
February 26, 2021, the Company entered into an amended and restated
employment agreement (the “Employment
Agreement Amendment”)
with the Company’s President and Chief Operating Officer,
Christopher Santi. Pursuant to the Employment Agreement Amendment,
Mr. Santi will continue to be employed as the Company’s President
and Chief Operating Officer through January 30, 2024. Mr.
Santi will receive a base salary of $0.4 million
for 2021 and his salary will increase 10% in
each subsequent year. The Term shall be automatically
renewed for successive one-year terms unless notice of non-renewal
is given by either party at least 30 days before the end of the
Term. The
above description of the terms of the Santi Employment Agreement is
not complete and is qualified by reference to the complete
document.
Legal Proceedings
Two lawsuits were filed against the Company and its subsidiaries in
connection with alleged claimed battery defects for an electronic
cigarette device. Plaintiffs claim these batteries were sold by a
store of the Company’s subsidiary and have sued for an undetermined
amount of damages (other than a total of $0.4 million of medical
costs). The initial complaints were filed between January 2019 and
April 2019. We responded to the complaints on April 2019 and May
2019, respectively. Given the lack of information presented by the
plaintiffs to date, the Company is unable to predict the outcome of
these matters and, at this time, cannot reasonably estimate the
possible loss or range of loss with respect to these legal
proceedings.
On
November 30, 2020, the Company filed a patent infringement lawsuit
against Philip Morris USA, Inc. and Philip Morris Products S.A. in
the U.S. District Court for the Northern District of Georgia.
The lawsuit alleges infringement on HCMC-owned patent(s) by the
Philip Morris product known and marketed as “IQOS®”. Philip
Morris claims that it is currently approaching 14
million
users of its IQOS® product and has reportedly invested over
$3 billion
in their smokeless tobacco products. On December 3, 2021,
the District Court for the Northern District of Georgia effectively
dismissed HCMC’s patent infringement action against Philip Morris
USA, Inc. and Philip Morris Products S.A. On December 14,
2021, the Company filed an appeal of the District Court for the
Northern District of Georgia’s dismissal of the Company’s patent
infringement action against Philip Morris USA, Inc. and Philip
Morris Products S.A. HCMC believes the Georgia Court committed
legal error by dismissing its complaint for patent infringement and
also by denying the Company’s motion to amend its pleading.
From time to time the Company is involved in legal proceedings
arising in the ordinary course of our business. We believe that
there is no other litigation pending that is likely to have,
individually or in the aggregate, a material adverse effect on our
financial condition or results of operations December 31, 2021.
With respect to legal costs, we record such costs as
incurred.
Fontem License Agreement
The Company has a non-exclusive license to certain products with
Fontem Ventures B.V. (“Fontem”). The Company will make quarterly
license and royalty payments in perpetuity to Fontem, based on the
sale of qualifying products as defined in the license agreement at
a royalty rate of 5.25%. For the years ended December 31, 2021 and
2020, the Company recorded expenses of $12,000 and $15,000 as part
of its cost of goods.
Note 13. STOCKHOLDERS’ EQUITY
Equity Compensation Plans
The Company’s 2015 Equity Incentive Plan, as amended (the “2015
Plan”), awards grants to employees. The plan can award up to 100
billion shares of common stock and currently 10.3 billion shares
are available for grant as of December 31, 2021.
The Company’s 2009 Equity Incentive Plan (the “2009 Plan”) awards
grants to employees, non-employee directors and consultants in
connection with their retention and/or continued employment by the
Company. The 2009 Plan had no shares of common stock available for
grant as of December 31, 2021.
On
June 18, 2021,
the Company issued 27,046,800,310 shares
of common stock in connection with the Rights Offering at a
subscription price of $0.0010 per
share, generating gross proceeds of $27.0 million.
The Company incurred direct financing costs of
$2.7 million
in connection with the offering resulting in net proceeds to the
Company of $24.3 million.
Exchange Agreement
On
March 29, 2021,
the Company entered into exchange agreements with the holders of
the $2.7 million
Loan and Security Agreement (the "Credit Agreement"). The agreement
with the holders of the Company’s indebtedness (the “Notes”) in an
aggregate amount of $1.3 million
to exchange the Notes for 1,172,964,218 shares
at a conversion price of $0.0011.
The Notes were issued pursuant to the Credit Agreement dated as
of August 18, 2020,
among The Vape Store, Inc., the Company, Healthy Choice Markets,
Inc., Sabby Healthcare Master Fund, Ltd., and Sabby Volatility
Warrant Master Fund, Ltd. In connection with the Exchange,
the Credit Agreement and all related loan documents was terminated
and the Holder’s on the assets of the Company and its subsidiaries
was cancelled.
The Company recognized a loss on debt extinguishment of
$0.1 million
for the year ended December 31, 2021.
Preferred Stock
The Company’s amended and restated articles of incorporation
authorizes the Company’s Board of Directors to issue up to
1,000,000 shares of “blank check” preferred stock, having a $0.001
par value, in one or more series without stockholder approval. Each
such series of preferred stock may have such number of shares,
designations, preferences, voting powers, qualifications, and
special or relative rights or privileges as determined by the
Company’s Board of Directors. See below for details associated with
the designation of the 1,000,000 shares of the Series A preferred
stock.
Series C Convertible Preferred Stock
On November 17, 2020, the Company finalized the closing of the
stock exchange with certain holders of its Series B Stock to
exchange all the Series B Stock for 20,150 shares of Series C
Convertible Preferred Stock (the “Series C Stock”). Each share of
Series C Stock has a stated value equal to $1,000 and is
convertible into Common Stock on a fixed basis at a conversion
price of $0.0001 per share.
During the years ended December 31, 2021 and 2020, the Company
issued 162.8 billion shares and 38.7 billion shares of Company
common stock in connection with the exercise of Series C
stock.
Series D Convertible Preferred Stock
On February
7, 2021,
the Company entered into a Securities Purchase Agreement, pursuant
to which the Company sold and issued 5,000 shares
of its Series D Convertible Preferred Stock (the “Preferred Stock”)
to accredited investors for $1,000 per
share or an aggregate subscription of $5.0 million.
As of December 31, 2021,
the Company has issued 6.6 billion
shares of Company common stock in connection with the exercise
of 4,200 shares
of the Series D Convertible Preferred Stock at a conversion price
of $0.00064 per
share. The conversion price for the exercise of the preferred stock
was reset to the 80% of
the lowest daily volume-weighted average price ("VWAP") during
the 5 Trading
Days immediately preceding the effective date of August 11,
2021.
Warrants
October 5, 2016, the Company’s amended and restated its Series A
Warrant Standstill Agreements (the "Amended Standstill Agreements")
to permit each holder (each, a "Holder") to effect a "cashless"
exercise of the Series A Warrants only on dates when the closing
bid price used to determine the "net number" of shares to be issued
upon exercise is at or above $0.00. The shares
issuable upon the exercise of the Series A Warrants are calculated
(1) using a Black Scholes Value of 1,517,936 per share and a
closing stock bid price at or above 0.00 and (2) the Company will
deliver only common stock upon exercise of the Series A
Warrants.
On July 27, 2020, the Company's Series A Warrants expired and the
balance of outstanding warrants not exercised was 355,661
warrants.
During the year ended December 31, 2020, the Company issued
3,466,153 shares of the Company Common Stock in connection with the
exercise of the Series A Warrant.
Modification of share-based payment awards to officers
On August 13, 2018, the Compensation Committee of the Company
approved a modification of share-based payment awards to the Chief
Executive Officer and Chief Operating Officer of the Company. As
part of the share modification, the Chief Executive Officer and
Chief Operating Officer were granted 11 billion and 8 billion
shares of restricted common stock on the condition that the same
number of shares from their options to purchase the Company’s
common stock are forfeited. However, the shares were issued to the
officers and have been reflected in the statement of stockholders’
equity. Initially, this restricted stock was schedule to vest one
year following the date of issuance provided that the grantee
remains an employee of the Company through the vesting date.
On August 12, 2019, the Company agreed to extend the expiration
date of the vesting period for the restricted stock by six months
to February 13, 2020.
On August 12, 2020, the Company agreed to extend for a second time
the expiration date of the vesting period for the restricted stock
by six months to February 13, 2021.
On January
14, 2021,
the Compensation Committee of the Company approved an issuance of
restricted stock to the Officers and a Director of the Company, in
consideration for agreeing to a new vesting schedule for the
existing awarded restricted stock. Each individual was granted
a 10% increase
from the original award agreement for a total
of 2.3 billion
shares of restricted common stock, which will vest quarterly in
equal amounts until December 31, 2022,
provided that the grantee remains an employee of the Company
through the vesting date.
Restricted Stock
On August 13, 2018, the Compensation Committee of the Company
approved an issuance of restricted stock to the Chief Financial
Officer (the "Officer") of the Company. The Officer was granted 3
billion shares of restricted common stock, which will vest one year
following the date of issuance, provided that the grantee remains
an employee of the Company through the vesting date.
On August 12, 2019, the Company agreed to extend the expiration
date of the vesting period for the restricted stock by six months
to February 13, 2020.
On August 12, 2020, the Company agreed to extend for a second time
the expiration date of the vesting period for the restricted stock
by six months to February 13, 2021.
On January
14, 2021,
the Compensation Committee of the Company approved an issuance of
restricted stock to the Officers and a Director of the Company, in
consideration for agreeing to a new vesting schedule for the
existing awarded restricted stock. Each individual was granted
a 10% increase
from the original award agreement for a total
of 2.3 billion
shares of restricted common stock, which will vest quarterly in
equal amounts until December 31, 2022,
provided that the grantee remains an employee of the Company
through the vesting date.
On
March 30, 2021,
the Company and the Officers and a Director of the Company agreed
to forfeit a total of 3.09 billion
of restricted shares of common stock that were due to vest
on March 31, 2021.
On
June 29, 2021,
the Company and the Officers and a Director of the Company agreed
to forfeit a total of 3.09 billion
of restricted shares of common stock that were due to vest
on June 30, 2021.
Stock Options
During the years ended December 31, 2021 and 2020, the Company did
not grant any options for the purchase of shares of its common
stocks.
A summary of option activity during the years ended December 31,
2021 and 2020 is as follows:
|
|
Number of Options
|
|
|
Weighted Average
Exercise
Price
|
|
|
Weighted Average Remaining Term (Yrs.)
|
|
|
Aggregate Intrinsic Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding, January 1, 2020
|
|
|
69,862,230,680
|
|
|
$
|
0.00
|
|
|
|
7
|
|
|
$
|
-
|
|
Options granted
|
|
|
-
|
|
|
|
0.00
|
|
|
|
|
|
|
|
-
|
|
Options forfeited or expired
|
|
|
-
|
|
|
|
0.00
|
|
|
|
|
|
|
|
-
|
|
Outstanding, December 31, 2020
|
|
|
69,862,230,680
|
|
|
$
|
0.00
|
|
|
|
6
|
|
|
$
|
-
|
|
Options granted
|
|
|
-
|
|
|
|
0.00
|
|
|
|
|
|
|
|
-
|
|
Options exercised
|
|
|
(2,275,000,000
|
)
|
|
|
0.00
|
|
|
|
|
|
|
|
-
|
|
Options forfeited or expired
|
|
|
-
|
|
|
|
0.00
|
|
|
|
|
|
|
|
-
|
|
Outstanding, December 31, 2021
|
|
|
67,587,230,680
|
|
|
$
|
0.00
|
|
|
|
5
|
|
|
|
-
|
|
Exercisable at December 31, 2021
|
|
|
67,587,230,680
|
|
|
$
|
0.00
|
|
|
|
5
|
|
|
$
|
-
|
|
During the years ended December 31, 2021 and 2020, the Company
recognized stock-based compensation expense of approximately
$34,375 and $78,029, respectively, in connection with the
amortization of stock options, net of recovery of stock-based
charges for forfeited stock options. Stock-based compensation
expense is included as part of selling, general and administrative
expense in the accompanying consolidated statements of
operations.
Income (Loss) per Share
Basic income (loss) per share is computed by dividing the net
income (loss) available to common stockholders by the weighted
average number of common shares outstanding during the period.
Diluted income (loss) per share is computed using the weighted
average number of common shares and, if dilutive, potential common
shares outstanding during the period. Potential common shares
consist of the incremental common shares issuable upon (a) the
exercise of stock options (using the treasury stock method); (b)
the conversion of Series A convertible preferred stock; (c) the
exercise of warrants (using the if-converted method); (d) the
vesting of restricted stock units; and (e) the conversion of
convertible notes payable. Diluted income (loss) per share excludes
the potential common shares, as their effect is antidilutive. The
following table summarizes the Company’s securities that have been
excluded from the calculation of basic and dilutive income (loss)
per share as their effect would be anti-dilutive:
|
|
December 31,
|
|
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
1,250,000,000
|
|
|
|
162,771,153,000
|
|
Stock options
|
|
|
67,587,230,680
|
|
|
|
69,862,230,680
|
|
Total
|
|
|
68,837,230,680
|
|
|
|
232,633,383,680
|
|
Note 14. LEASE
The Company has various lease agreements with terms up to 20 years,
including leases of retail stores, headquarter and equipment. All
the leases are classified as operating leases.
The following table presents information about the amount, timing
and uncertainty of cash flows arising from the Company’s operating
leases as of December 31, 2021.
Maturity of Lease Liabilities by Fiscal Year
|
|
|
|
2022
|
|
$
|
572,335
|
|
2023
|
|
|
450,877
|
|
2024
|
|
|
342,005
|
|
2025
|
|
|
337,685
|
|
2026
|
|
|
267,759
|
|
Thereafter
|
|
|
1,941,250
|
|
Total undiscounted operating lease payments
|
|
$
|
3,911,911
|
|
Less: Imputed interest
|
|
|
(789,562
|
|